23andMe Holding (ME) 10-Q 8 Aug 23 2024 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Jun. 30, 2023	Jul. 31, 2023
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Fiscal Period Focus	Q1
Document Period End Date	Jun. 30, 2023
Document Fiscal Year Focus	2023
Document Quarterly Report	true
Document Transition Report	false
Entity Registrant Name	23ANDME HOLDING CO
Entity Central Index Key	0001804591
Entity File Number	001-39587
Entity Tax Identification Number	87-1240344
Entity Incorporation, State or Country Code	DE
Current Fiscal Year End Date	--03-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Shell Company	false
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Address, Address Line One	349 Oyster Point Boulevard
Entity Address, City or Town	South San Francisco,
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94080
Local Phone Number	938-6300
City Area Code	650
Title of 12(b) Security	Class A common stock, $0.0001 par value per share
Trading Symbol	ME
Security Exchange Name	NASDAQ
Class A Common Stock [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		304,927,539
Class B Common Stock [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		167,563,092

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2023	Mar. 31, 2023
Current assets:
Cash and cash equivalents	$ 314,351	$ 386,849
Restricted cash	1,399	1,399
Accounts receivable, net	4,124	1,897
Inventories	11,815	10,247
Deferred cost of revenue	7,301	5,376
Prepaid expenses and other current assets	21,286	19,224
Total current assets	360,276	424,992
Property and equipment, net	35,704	38,608
Operating lease right-of-use assets	54,329	56,078
Restricted cash, noncurrent	6,974	6,974
Internal-use software, net	17,882	15,661
Intangible assets, net	41,678	45,520
Goodwill	351,744	351,744
Other assets	2,612	3,021
Total assets	871,199	942,598
Current liabilities:
Accounts payable (includes related party amounts of $3,510 and $3,186, respectively)	12,748	12,924
Accrued expenses and other current liabilities (includes related party amounts of $5,523 and $8,738, respectively)	50,215	66,430
Deferred revenue (includes related party amounts of $1,082 and $11,753, respectively)	48,123	62,521
Operating lease liabilities	7,823	7,541
Total current liabilities	118,909	149,416
Operating lease liabilities, noncurrent	75,412	77,763
Other liabilities	1,388	1,480
Total liabilities	195,709	228,659
Commitments and contingencies (Note 11)
Stockholders' equity
Preferred stock - par value $0.0001, 10,000,000 shares authorized as of June 30, 2023 and March 31, 2023; zero shares issued and outstanding as of June 30, 2023 and March 31, 2023	0	0
Common stock, par value $0.0001 - Class A shares, 1,140,000,000 shares authorized, 304,011,272 and 293,020,474 shares issued and outstanding as of June 30, 2023 and March 31, 2023, respectively; Class B shares, 350,000,000 shares authorized, 168,084,278 and 168,179,488 shares issued and outstanding as of June 30, 2023 and March 31, 2023, respectively	47	46
Additional paid-in capital	2,287,405	2,220,897
Accumulated other comprehensive loss	(954)	(620)
Accumulated deficit	(1,611,008)	(1,506,384)
Total stockholders' equity	675,490	713,939
Total liabilities and stockholders' equity	$ 871,199	$ 942,598

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2023	Mar. 31, 2023
Deferred revenue, current, related party	$ 1,082	$ 11,753
Accounts payable related party	3,510	3,186
Accrued expenses and other current liabilities, related party	$ 5,523	$ 8,738
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Class A Common Stock [Member]
Common stock, shares authorized	1,140,000,000	1,140,000,000
Common stock, shares issued	304,011,272	293,020,474
Common stock, shares outstanding	304,011,272	293,020,474
Class B Common Stock [Member]
Common stock, shares authorized	350,000,000	350,000,000
Common stock, shares issued	168,084,278	168,179,488
Common stock, shares outstanding	168,084,278	168,179,488

Condensed Consolidated Statemen

Condensed Consolidated Statements Of Operations And Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Revenue (includes related party revenue of $10,670 and $8,265, respectively)	$ 60,864	$ 64,513
Cost of revenue (includes related party cost of $275 and $(239), respectively)	30,184	39,023
Gross profit	30,680	25,490
Operating expenses:
Research and development (includes related party expenses of $3,301 and $3,549, respectively)	62,329	52,009
Sales and marketing	22,658	33,434
General and administrative	50,740	29,643
Restructuring charges incurred during the period	4,217	0
Total operating expenses	139,944	115,086
Loss from operations	(109,264)	(89,596)
Other income (expense):
Interest income, net	4,307	245
Other income (expense), net	333	(435)
Loss before income taxes	(104,624)	(89,786)
Benefit from income taxes	0	254
Net loss	(104,624)	(89,532)
Other comprehensive (loss) income, net of tax	(334)	624
Total comprehensive loss	$ (104,958)	$ (88,908)
Net loss per share of Class A and Class B common stock attributable to common stockholders:
Net loss per share attributable to common stockholders, basic	$ (0.23)	$ (0.20)
Net loss per share attributable to common stockholders, diluted	$ (0.23)	$ (0.20)
Weighted-average shares used to compute net loss per share:
Weighted-average shares used to compute net loss per share, basic	462,254,442	446,505,329
Weighted-average shares used to compute net loss per share, diluted	462,254,442	446,505,329

Condensed Consolidated Statem_2

Condensed Consolidated Statements Of Operations And Comprehensive Loss (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Revenue from related party	$ 10,670	$ 8,265
Related party cost of revenue	(275)	(239)
Related party research and development expense	$ 3,301	$ 3,549

Condensed Consolidated Statem_3

Condensed Consolidated Statements Of Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income Loss	Accumulated Deficit [Member]
Beginning Balance at Mar. 31, 2022	$ 915,656	$ 45	$ 2,110,160	$ 179	$ (1,194,728)
Beginning Balance, Shares at Mar. 31, 2022		448,812,321
Issuance of common stock related to early exercise of stock options	1,533		1,533
Issuance of common stock related to early exercise of stock options, shares		1,065,784
Issuance of common stock upon release of restricted stock units, shares		1,461,448
Net share settlements for stock-based minimum tax withholdings, value		(14,036)
Stock-based compensation expense	25,915		25,915
Other comprehensive loss	624			624
Net loss	(89,532)				(89,532)
Ending Balance at Jun. 30, 2022	854,196	$ 45	2,137,608	803	(1,284,260)
Ending Balance, Shares at Jun. 30, 2022		451,325,517
Beginning Balance at Mar. 31, 2023	713,939	$ 46	2,220,897	(620)	(1,506,384)
Beginning Balance, Shares at Mar. 31, 2023		461,199,962
Issuance of common stock related to early exercise of stock options	$ 85		85
Issuance of common stock related to early exercise of stock options, shares	180,718	180,718
Issuance of common stock upon release of restricted stock units, shares		1,812,802
Issuance of common stock upon release of restricted stock units under the 2022 Annual Incentive Plan (Shares)		8,961,053
Issuance of common stock upon release of restricted stock units under the 2022 Annual Incentive Plan	$ 18,630	$ 1	18,629
Net share settlements for stock-based minimum tax withholdings, value		(58,985)
Net share settlements for stock-based minimum tax withholdings, shares	(121)		(121)
Stock-based compensation expense	47,915		47,915
Other comprehensive loss	(334)			(334)
Net loss	(104,624)				(104,624)
Ending Balance at Jun. 30, 2023	$ 675,490	$ 47	$ 2,287,405	$ (954)	$ (1,611,008)
Ending Balance, Shares at Jun. 30, 2023		472,095,550

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities:
Net loss	$ (104,624)	$ (89,532)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	6,868	8,360
Amortization and impairment of internal-use software	1,248	1,052
Stock-based compensation expense	51,100	30,462
Loss (gain) on disposal of property and equipment	(5)	(9)
Changes in operating assets and liabilities:
Accounts receivable, net	(2,227)	460
Inventories	(1,568)	(673)
Deferred cost of revenue	(1,925)	1,154
Prepaid expenses and other current assets	(1,928)	7,259
Operating lease right-of-use assets	1,749	1,833
Other assets	408	(765)
Accounts payable (included related party amounts of $325 and $12,567, respectively)	(2)	(19,154)
Accrued expenses and other current liabilities (included related party amounts of $-3215 and $3,310, respectively)	(1,889)	2,454
Deferred revenue (included related party amounts of $-10,670 and $(8,246), respectively)	(14,398)	(13,116)
Operating lease liabilities	(2,070)	(2,179)
Other liabilities	(92)	(664)
Net cash used in operating activities	(69,355)	(73,040)
Cash flows from investing activities:
Purchases of property and equipment	(419)	(1,614)
Proceeds from sale of property and equipment	5	0
Capitalized internal-use software costs	(2,281)	(1,286)
Net cash used in investing activities	(2,695)	(2,900)
Cash flows from financing activities:
Proceeds from exercise of stock options	69	1,533
Payments of deferred offering costs	(62)	0
Payments for taxes related to net share settlement of equity awards	(121)	0
Net cash (used in) provided by financing activities	(114)	1,533
Effect of exchange rates on cash and cash equivalents	(334)	623
Net decrease in cash, cash equivalents and restricted cash	(72,498)	(73,784)
Cash, cash equivalents and restricted cash-beginning of period	395,222	561,755
Cash, cash equivalents and restricted cash-end of period	322,724	487,971
Supplemental disclosures of non-cash investing and financing activities:
Purchases of property and equipment included in accounts payable and accrued expenses	176	28
Stock-based compensation capitalized for internal-use software costs	1,188	573
Issuance of common stock upon release of restricted stock units under the 2022 Annual Incentive Plan	18,630
Deferred offering costs during the period included in accounts payable and accrued expenses	100	0
Cash and cash equivalents	314,351	479,398
Restricted cash, current	1,399	1,599
Restricted cash, noncurrent	6,974	6,974
Total cash, cash equivalents and restricted cash	$ 322,724	$ 487,971

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Accounts Payable
Related party amounts	$ 325	$ (12,567)
Accrued Expenses And Other Current Liabilities
Related party amounts	3,215	3,310
Deferred Revenue
Related party amounts	$ 10,670	$ (8,246)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Jun. 30, 2023
Insider Trading Arrangements [LineI tem]
Material Terms of Trading Arrangement	None of the Company’s directors or officers adopted , modified, or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the Company’s fiscal quarter ended June 30, 2023
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Organization and Description of

Organization and Description of Business	3 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Organization, Consolidation and Presentation of Financial Statements	1. Organization and Description of Business 23andMe Holding Co. (the “Company” or “23andMe”) is dedicated to helping people access, understand, and benefit from the human genome. The Company is building the leading direct-to-consumer precision medicine platform that powers its genetics driven therapeutics and research business. The Company is dedicated to empowering customers to live healthier lives by providing consumers direct access to their genetic information, and digital access to affordable personalized healthcare through the Lemonaid Health, Inc. ("Lemonaid Health") platform. The Company pioneered direct-to-consumer genetic testing, giving consumers unique, personalized information about their genetic health risks, ancestry, and traits. It was the first company to obtain Food and Drug Administration (“FDA”) authorization for a direct-to-consumer genetic test, and is the only company to have FDA authorization, clearance, or an exemption from premarket notification for all of the carrier status, genetic health risk, cancer predisposition, and pharmacogenetics reports that the Company offers to customers. Through the Lemonaid Health telehealth platform, the Company connects patients to licensed healthcare professionals to provide affordable and direct online access to medical care, from consultation through treatment, for a number of common conditions, using evidence-based guidelines and up-to-date clinical protocols. When medications are prescribed by Lemonaid Health’s affiliated healthcare professionals, patients can use Lemonaid Health’s online pharmacy for fulfillment. Patients also can access telehealth consultations for certain 23andMe genetic reports through Lemonaid Health. 23andMe, Inc., the Company’s accounting predecessor, was incorporated in Delaware in 2006. The Company is headquartered in South San Francisco, California. The Company’s predecessor, VG Acquisition Corp. (“VGAC”), was a blank check company originally incorporated in 2020 as a Cayman Islands exempted company. On June 16, 2021 (the “Closing Date”), VGAC and Chrome Merger Sub, Inc., a Delaware corporation and wholly owned direct subsidiary of VGAC (“Merger Sub”), consummated a merger with 23andMe, Inc. (the “Merger”), whereby Merger Sub merged with and into 23andMe, Inc., with 23andMe, Inc. being the surviving corporation and a wholly owned subsidiary of the Company. In connection with the Merger, VGAC changed its jurisdiction of incorporation from the Cayman Islands to the State of Delaware and changed its name to 23andMe Holding Co. (the “Domestication” and, together with the Merger, the “Business Combination”). The Company has evaluated how it is organized and managed and has identified two reporting segments: Consumer and Research Services, and Therapeutics.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation and Principle of Consolidation The Company’s unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and include the accounts of the Company and its wholly owned subsidiaries, and variable interest entities in which it holds a controlling financial interest. All intercompany accounts and transactions have been eliminated in consolidation. For the three months ended June 30, 2023 and 2022, the Company’s operations were primarily in the United States, with immaterial operations in the United Kingdom (“U.K.”). There have been no material changes to the Company's significant accounting policies for the three months ended June 30, 2023 , as compared to the audited consolidated financial statements in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2023. Unaudited Interim Condensed Consolidated Financial Information The accompanying interim condensed consolidated financial statements as of June 30, 2023 and for the three months ended June 30, 2023 and 2022 and accompanying notes, are unaudited. These unaudited interim condensed consolidated financial statements (the “condensed consolidated financial statements”) have been prepared in accordance with GAAP applicable to interim financial statements. These financial statements are presented in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) and do not include all disclosures normally required in annual consolidated financial statements prepared in accordance with GAAP. As such, the information included herein should be read in conjunction with the consolidated financial statements and accompanying notes as of and for the fiscal year ended March 31, 2023 (the “audited consolidated financial statements”) that were included in the Company’s Annual Report on Form 10-K filed with the SEC on May 25, 2023. In management’s opinion, the unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements, which include only normal recurring adjustments, necessary for a fair statement of the Company’s financial position as of June 30, 2023 and its condensed consolidated results of operations and cash flows for the three months ended June 30, 2023 and 2022. The results of operations for the three months ended June 30, 2023 are not necessarily indicative of the results expected for the year ending March 31, 2024 or any other future interim or annual periods. Fiscal Year The Company’s fiscal year ends on March 31. References to fiscal 2024 refer to the fiscal year ending March 31, 2024 and references to fiscal 2023 and fiscal 2022 refer to the fiscal years ended March 31, 2023 and March 31, 2022, respectively. Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities and the related disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period and the accompanying notes. Significant items subject to such estimates and assumptions include, but are not limited to the determination of standalone selling price for various performance obligations; the estimated expected benefit period for the rate and recognition pattern of breakage revenue for purchases where a saliva collection kit (“Kit”) is never returned for processing; the capitalization and estimated useful life of internal use software; the useful life of long-lived assets; fair value of intangible assets acquired in business combinations; the carrying value of goodwill; the incremental borrowing rate for operating leases; stock-based compensation including the determination of the fair value of stock options, annual incentive bonuses payable in the form of restricted stock units (“RSUs”), as well as the Company’s common stock prior to the Closing Date of the Merger; and the valuation of deferred tax assets and uncertain tax positions. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that it believes are reasonable under the circumstances, including assumptions as to future events. Actual results could differ from these estimates, and such differences could be material to the condensed consolidated financial statements. The Company is not aware of any specific event or circumstance that would require revisions to estimates, updates to judgments, or adjustments to the carrying value of assets or liabilities. These estimates may change, as new events occur and additional information is obtained, and will be recognized in the condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the condensed consolidated financial statements. Concentration of Supplier Risk Certain of the raw materials, components and equipment associated with the deoxyribonucleic acid (“DNA”) microarrays and Kits used by the Company in the delivery of its services are available only from third-party suppliers. The Company also relies on a third-party laboratory service for the processing of its customer samples. Shortages and slowdowns could occur in these essential materials, components, equipment, and laboratory services due to an interruption of supply or increased demand in the industry. If the Company were unable to procure certain materials, components, equipment, or laboratory services at acceptable prices, it would be required to reduce its laboratory operations, which could have a material adverse effect on its results of operations. A single supplier accounted for 100 % of the Company’s total purchases of microarrays and a separate single supplier accounted for 100 % of the Company’s total purchases of Kits for the three months ended June 30, 2023 and 2022 . One laboratory service provider accounted for 100 % of the Company’s processing of customer samples for the three months ended June 30, 2023 and 2022 . Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk include cash, cash equivalents and accounts receivable. The Company maintains a majority of its cash and cash equivalents with a single high-quality financial institution, the composition and maturities of which are regularly monitored by the Company. The Company’s revenue and accounts receivable are derived primarily from the United States. See Note 3, “ Revenue, ” for additional information regarding geographical disaggregation of revenue. The Company grants credit to its customers in the normal course of business, performs ongoing credit evaluations of its customers, and does not require collateral. The Company regularly monitors the aging of accounts receivable balances. Significant customer information is as follows: June 30, March 31, Percentage of accounts receivable: Customer C (1) 66 % 69 % Customer F * 27 % Customer G 12 % * Customer H 12 % * * less than 10% (1) Customer C is a reseller. Three Months Ended June 30, 2023 2022 Percentage of revenue: Customer C (1) 16 % 15 % Customer B 18 % 13 % (1) Customer C is a reseller. Restructuring The Company defines restructuring expenses to include costs directly associated with exit or disposal activities, such as severance payments, benefits continuation, and non-cash stock-compensation charges associated with the modification of certain stock awards. In general, the Company records involuntary employee-related exit and disposal costs when it communicates to employees that they are entitled to receive such benefits and the amount can be reasonably estimated. Liquidity The Company’s operations have been financed primarily through the sales of equity securities and revenue from sales of PGS, telehealth, and research services. During fiscal 2022, the Company received gross proceeds of $ 309.7 million from the Merger and $ 250.0 million from the PIPE investment consummated in connection with the Merger. The Company expects to continue to incur operating losses and negative cash flows from operations for the foreseeable future due to the investments it intends to continue to make in research and development, along with general and administrative, and sales and marketing, expenses incurred to capitalize on market opportunities and drive long-term growth. The Company may require additional financing to fund operations to meet its business plan. As of June 30, 2023, the Company had cash and cash equivalents of $ 314.4 million. Based on current cash resources and the implementation of a previously-disclosed reduction in force in June 2023, the Company believes its cash and cash equivalents will be sufficient to fund estimated operating expenses and capital expenditure requirements for at least 12 months from the date of the issuance of these condensed consolidated financial statements. Management considers that there are no conditions or events in the aggregate that raise substantial doubt about the Company’s ability to continue as a going concern for a period of at least one year from the date the condensed consolidated financial statements are issued.

Revenue

Revenue	3 Months Ended
	Jun. 30, 2023
Disaggregation of Revenue [Abstract]
Revenue	3. Revenue Disaggregation of Revenue The following table presents revenue by category: Three Months Ended June 30, 2023 2022 Amount % of Revenue Amount % of Revenue (in thousands, except percentages) Point in Time PGS $ 31,759 52 % $ 39,691 61 % Telehealth 8,285 14 % 9,361 15 % Consumer services 40,044 66 % 49,052 76 % Research services 2,353 3 % — 0 % Total $ 42,397 69 % $ 49,052 76 % Over Time PGS $ 5,270 9 % $ 4,484 7 % Telehealth 2,238 4 % 2,523 4 % Consumer services 7,508 13 % 7,007 11 % Research services 10,959 18 % 8,454 13 % Total $ 18,467 31 % $ 15,461 24 % Revenue by Category PGS $ 37,029 61 % $ 44,175 68 % Telehealth 10,523 18 % 11,884 19 % Consumer services 47,552 79 % 56,059 87 % Research services 13,312 21 % 8,454 13 % Total $ 60,864 100 % $ 64,513 100 % The following table summarizes revenue by region based on the shipping address of customers or the location where the services are delivered: Three Months Ended June 30, 2023 2022 Amount % of Revenue Amount % of Revenue (in thousands, except percentages) United States $ 43,326 71 % $ 48,108 75 % United Kingdom 14,355 24 % 11,975 19 % Canada 2,170 3 % 3,039 4 % Other regions 1,013 2 % 1,391 2 % Total $ 60,864 100 % $ 64,513 100 % Breakage Revenue The Company sells through multiple channels, including direct-to-consumer via the Company’s website and through online retailers. If the customer does not return the Kit for processing, services cannot be completed by the Company, potentially resulting in unexercised rights (“breakage”) revenue. The Company recognized breakage revenue from unreturned Kits of $ 4.6 million and $ 5.0 million for the three months ended June 30, 2023 and 2022, respectively. Contract Balances Accounts receivable are recorded when the right to consideration becomes unconditional. Contract assets include amounts associated with contractual rights related to consideration for performance obligations and are included in prepaid expenses and other current assets on the condensed consolidated balance sheets. The amount of contract assets was immaterial as of June 30, 2023 and March 31, 2023. Contract liabilities consist of deferred revenue. As of June 30, 2023 and March 31, 2023, deferred revenue for consumer services was $ 45.9 million and $ 48.6 million, respectively. Of the $ 48.6 million of deferred revenue for consumer services as of March 31, 2023, the Company recognized $ 22.5 million as revenue during the three months ended June 30, 2023. As of June 30, 2023 and March 31, 2023, deferred revenue for research services was $ 2.2 million and $ 14.0 million, respectively, which included related party deferred revenue amounts of $ 1.1 million and $ 11.8 million, respectively. Of the $ 14.0 million of deferred revenue for research services as of March 31, 2023, the Company recognized $ 12.4 million as revenue during the three months ended June 30, 2023, which included related party revenue amounts of $ 10.7 million. Remaining Performance Obligations The transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized, which includes deferred revenue and amounts that are expected to be billed and recognized as revenue in future periods. The Company has utilized the practical expedient available under Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”) to not disclose the value of unsatisfied performance obligations for PGS and telehealth as those contracts have an expected length of one year or less. As of June 30, 2023, the aggregate amount of the transaction price allocated to remaining performance obligations for research services was $ 3.1 million. The Company expects to recognize revenue of approximately 81 % of this amount over the next 12 months and the remainder thereafter. During the three months ended June 30, 2023 and 2022 , the Company did not recognize any revenue for performance obligations satisfied in prior periods.

Collaborations

Collaborations	3 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaborations	. Collaborations GlaxoSmithKline Agreement In July 2018, the Company and an affiliate of GlaxoSmithKline (“GSK”) entered into a four-year exclusive drug discovery and development collaboration agreement (the “GSK Agreement”) for collaboration on identification and development of therapeutic agents with a unilateral option for GSK to extend the term for an additional year. In January 2022, GSK elected to exercise the option to extend the exclusive target discovery term for an additional year to July 2023. In October 2022, the Company received a one-time payment of $ 50.0 million from GSK in consideration of the exercise of the option pursuant to the GSK Agreement. The exclusive drug discovery period under the GSK Agreement expired on July 23, 2023. The Company concluded that GSK is considered a customer. Therefore, the Company has applied the guidance in ASC 606 to account for and present consideration received from GSK related to research services provided by the Company. The Company’s activities under the GSK Agreement, which include reporting, drug target discovery, and joint steering committee participation, represent one combined performance obligation to deliver research services. In addition, the GSK Agreement, along with subsequent amendments, provided GSK the right to include certain identified pre-existing Company programs in the collaboration at GSK’s election, each of which is considered distinct from the research services. The Company recognizes research services revenue related to the GSK Agreement as the performance obligation is satisfied using an input method to measure progress. The Company believes that actual hours incurred relative to projected hours is the most accurate measurement of progress for the input method. In addition to cost-sharing during the performance of research services which is recorded within cost of revenue when incurred in the Consumer and Research Services segment, once drug targets have been identified for inclusion in the collaboration, the Company and GSK equally share in the costs of further research, development, and commercialization of identified targets, subject to certain rights of either party to opt-out of funding at certain predetermined development milestones. These cost-sharing charges for costs incurred subsequent to the identification of drug targets have been included in research and development expense on the condensed consolidated statements of operations and comprehensive loss during the period incurred. The Company may also share in the net profits or losses of products that are commercialized pursuant to the collaboration or receive royalties on products which are successfully commercialized. The Company recognized research services revenue related to the GSK Agreement of $ 10.7 million and $ 8.3 million during the three months ended June 30, 2023 and 2022, respectively. As of June 30, 2023 and March 31, 2023, the Company had deferred revenue, all of which was current, related to the GSK Agreement of $ 1.1 million and $ 11.8 million, respectively. Cost-sharing amounts incurred prior to the identification of targets included in cost of revenue were $ 0.3 million and $ ( 0.2 ) million during the three months ended June 30, 2023 and 2022, respectively. Cost-sharing amounts incurred subsequent to the identification of targets, included in research and development expenses, were $ 3.3 million and $ 3.5 million during the three months ended June 30, 2023 and 2022, respectively. As of June 30, 2023 and March 31, 2023, the Company had $ 9.0 million and $ 11.9 million, respectively, related to balances of amounts payable to GSK for reimbursement of shared costs included within accounts payable and accrued expenses and other current liabilities on the condensed consolidated balance sheets. GSK’s affiliate, Glaxo Group Limited, held shares of the Company's Class B common stock representing 20.0 % and 20.1 % of the Company's combined voting power as of June 30, 2023 and March 31, 2023 , respectively; therefore, GSK is considered as a related party to the Company.

Segment Information

Segment Information	3 Months Ended
	Jun. 30, 2023
Segment Reporting [Abstract]
Segment Information	5. Segment Information The Company currently operates in two reporting segments: Consumer and Research Services, and Therapeutics. The Consumer and Research Services segment consists of revenue and expenses from PGS and telehealth, as well as research services revenue and expenses from certain collaboration agreements (including the GSK Agreement). The Therapeutics segment consists of revenues from the out-licensing of intellectual property associated with identified drug targets and expenses related to therapeutic product candidates under clinical development. Substantially all of the Company’s revenues are derived from the Consumer and Research Services segment. See Revenue Recognition in Note 3, “ Revenue, ” for additional information regarding revenue. There are no inter-segment sales. Certain department expenses such as Finance, Legal, Regulatory and Supplier Quality, Corporate Communications, Corporate Development, and CEO Office are not reported as part of the reporting segments as reviewed by the CODM (as defined below). These amounts are included in Unallocated Corporate in the reconciliations below. The chief operating decision-maker (“CODM”) is the Chief Executive Officer (“CEO”). The CODM evaluates the performance of each segment based on Adjusted EBITDA. Adjusted EBITDA is a non-GAAP financial measure that is defined as net income (loss) before net interest income (expense), net other income (expense), income tax expenses (benefit), depreciation and amortization, impairment charges, stock-based compensation expense, transaction-related costs, and other items that are considered unusual or not representative of underlying trends of our business, including but not limited to: changes in fair value of warrant liabilities and litigation settlements, if applicable for the periods presented. Adjusted EBITDA is a key measure used by the Company’s management and Board of Directors to understand and evaluate the Company’s operating performance and trends, to prepare and approve the annual budget, and to develop short-term and long-term operating plans. The Company’s revenue and Adjusted EBITDA by segment is as follows: Three Months Ended June 30, 2023 2022 (in thousands) Segment Revenue: (1) Consumer and Research Services $ 60,864 $ 64,513 Total revenue $ 60,864 $ 64,513 Segment Adjusted EBITDA: Consumer and Research Services Adjusted EBITDA $ ( 5,602 ) $ ( 16,997 ) Therapeutics Adjusted EBITDA ( 31,138 ) ( 18,465 ) Unallocated Corporate (2) ( 13,060 ) ( 14,253 ) Total Adjusted EBITDA $ ( 49,800 ) $ ( 49,715 ) Reconciliation of net loss to Adjusted EBITDA: Net loss $ ( 104,624 ) $ ( 89,532 ) Adjustments: Interest income, net ( 4,307 ) ( 245 ) Other (income) expense, net ( 333 ) 435 Income tax benefit — ( 254 ) Depreciation and amortization 4,478 5,104 Amortization of acquired intangible assets 3,638 4,315 Stock-based compensation expense 51,100 30,462 Transaction-related costs (3) 248 — Total Adjusted EBITDA $ ( 49,800 ) $ ( 49,715 ) (1) There was no Therapeutics revenue for the three months ended June 30, 2023 and 2022. (2) Certain department expenses such as Finance, Legal, Regulatory and Supplier Quality, Corporate Communications, Corporate Development, and CEO Office are not reported as part of the reporting segments as reviewed by the CODM. These amounts are included in Unallocated Corporate. (3) Refer to Note 17, “ Subsequent Events ” for additional information . Customers accounting for 10% or more of segment revenues were as follows: Three Months Ended June 30, 2023 2022 (in thousands) Consumer and Research Services Segment Revenue: Customer C (1) (2) $ 9,711 16 % $ 9,628 15 % Customer B (3) $ 10,670 18 % $ 8,246 13 % (1) Customer C is a reseller. (2) Customer C revenues are primarily in the United States. (3) Customer B revenues are in the U.K. Revenue by geographical region can be found in the revenue recognition disclosures in Note 3, “ Revenue. ” Substantially all of the Company’s property and equipment, net of depreciation and amortization, was located in the United States during the periods presented. The reporting segments do not present total assets as they are not reviewed by the CODM when evaluating their performance.

Variable Interest Entities

Variable Interest Entities	3 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Variable Interest Entities	6. Variable Interest Entities In providing telehealth services that include professional medical consultations, the Company maintains relationships with various affiliated professional medical corporations (“PMCs”). Additionally, with respect to its telehealth services involving the sale of prescription products, the Company maintains relationships with affiliated pharmacies (collectively, the “Affiliated Pharmacies”) to fill prescriptions that are ordered by the Company’s patients. The Company determined that the PMCs and Affiliated Pharmacies are variable interest entities (“VIEs”) due to the respective equity holders having nominal capital at risk, and the Company has a variable interest in each of the PMCs and Affiliated Pharmacies. The Company consolidated the PMCs and Affiliated Pharmacies under the VIE model since the Company has the power to direct activities that most significantly impact the VIEs’ economic performance and the right to receive benefits or the obligation to absorb losses that could potentially be significant to the VIEs. Under the VIE model, the Company presents the results of operations and the financial position of the VIEs as part of the condensed consolidated financial statements of the Company. Furthermore, as a direct result of the financial support the Company provides to the VIEs (e.g., loans), the interests held by holders lack economic substance and do not provide them with the ability to participate in the residual profits or losses generated by the VIEs. Therefore, all income and expenses recognized by the VIEs are allocated to the Company’s stockholders. The aggregate carrying value of total assets and total liabilities included on the condensed consolidated balance sheets for the VIEs after elimination of intercompany transactions were not material as of June 30, 2023 and March 31, 2023. Total revenue included on the condensed consolidated statements of operations and comprehensive loss for the VIEs after elimination of intercompany transactions was $ 9.0 million and $ 10.7 million for the three months ended June 30, 2023 and 2022, respectively. Net loss attributable to the VIEs included on the condensed consolidated statements of operations and comprehensive loss was $ 2.6 million and $ 0.4 million for the three months ended June 30, 2023 and 2022 , respectively.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	. Fair Value Measurements Recurring Fair Value Measurements The fair value of cash, restricted cash, accounts receivable, accounts payable, and accrued liabilities are stated at their carrying value, which approximates fair value due to the short time to the expected receipt or payment date as of June 30, 2023 and March 31, 2023. The following table presents information about the Company’s financial instruments that are measured at fair value on a recurring basis as of June 30, 2023 and March 31, 2023: June 30, 2023 March 31, 2023 Fair Value Level 1 Level 2 Level 3 Fair Value Level 1 Level 2 Level 3 (in thousands) Financial Assets: Money market funds $ 305,500 $ 305,500 $ — $ — $ 372,000 $ 372,000 $ — $ — Total financial assets $ 305,500 $ 305,500 $ — $ — $ 372,000 $ 372,000 $ — $ — Cash equivalents consist primarily of money market funds and are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets. As of June 30, 2023 , the Company had no transfers between levels of the fair value hierarchy of its assets and liabilities measured at fair value. Nonrecurring Fair Value Measurements Identifiable assets and liabilities acquired or assumed are measured separately at their fair values as of the acquisition date. Certain of the Company’s assets, including intangible assets and goodwill, are measured at fair value on a nonrecurring basis. During fiscal 2023, the Company recorded a $ 10.0 million impairment charge to write down the value of the U.K. partnership acquired intangible asset to its estimated fair value. There were no impairment charges during the three months ended June 30, 2023 and 2022.

Balance Sheet Components

Balance Sheet Components	3 Months Ended
	Jun. 30, 2023
Balance Sheet Related Disclosures [Abstract]
Balance Sheet Components	8. Balance Sheet Components Property and Equipment, Net Property and equipment, net consisted of the following: June 30, 2023 March 31, 2023 (in thousands) Computer and software $ 10,015 $ 10,376 Laboratory equipment and software 52,689 52,785 Furniture and office equipment 8,953 8,946 Leasehold improvements 40,955 40,964 Capitalized asset retirement obligations 853 853 Property and equipment, gross 113,465 113,924 Less: accumulated depreciation and amortization ( 77,761 ) ( 75,316 ) Property and equipment, net $ 35,704 $ 38,608 Depreciation and amortization expense was $ 3.0 million and $ 3.8 million for the three months ended June 30, 2023 and 2022, respectively. Internal-Use Software, Net Internal-use software, net consisted of the following: June 30, 2023 March 31, 2023 (in thousands) Capitalized internal-use software $ 28,649 $ 25,180 Less: accumulated amortization ( 10,767 ) ( 9,519 ) Internal-use software, net $ 17,882 $ 15,661 During the three months ended June 30, 2023 and 2022, the Company capitalize d $ 3.5 million and $ 1.9 million, respectively, in internal-use software. For the three months ended June 30, 2023 and 2022 , amortization and impairment of internal-use software was $ 1.2 million and $ 1.2 million, respectively. Intangible Assets, Net Intangible assets, net consisted of the following: June 30, 2023 Weighted Average Remaining Useful Life Gross Carrying Amount Accumulated Amortization Net Carrying Amount (in thousands, except years) Customer relationships 0.3 $ 14,900 $ ( 12,417 ) $ 2,483 Partnerships 8.3 9,000 ( 1,500 ) 7,500 Trademark 3.3 11,000 ( 3,666 ) 7,334 Developed technology 5.3 24,100 ( 5,738 ) 18,362 Non-compete agreements 3.3 2,800 ( 933 ) 1,867 Patents 5.2 5,500 ( 1,368 ) 4,132 Total intangible assets $ 67,300 $ ( 25,622 ) $ 41,678 March 31, 2023 Weighted Average Remaining Useful Life Gross Carrying Amount Accumulated Amortization Cumulative Impairment Charge Cumulative Currency Translation Net Carrying Amount (in thousands, except years) Customer relationships 0.6 $ 14,900 $ ( 10,554 ) $ — $ — $ 4,346 Partnerships 8.6 23,200 ( 4,385 ) ( 9,968 ) ( 1,122 ) 7,725 Trademark 3.6 11,000 ( 3,117 ) — — 7,883 Developed technology 5.6 24,100 ( 4,877 ) — — 19,223 Non-compete agreements 3.6 2,800 ( 793 ) — — 2,007 Patents 5.5 5,500 ( 1,164 ) — — 4,336 Total intangible assets $ 81,500 $ ( 24,890 ) $ ( 9,968 ) $ ( 1,122 ) $ 45,520 Amortization expense for intangible assets was $ 3.8 million and $ 4.5 million for the three months ended June 30, 2023 and 2022, respectively. During the third quarter of fiscal 2023, due to decreased revenue associated with a delayed product launch and margin forecasts for the U.K. partnership business, the Company performed an interim quantitative impairment test for the U.K. partnership asset group as of December 31, 2022. The fair value of the asset group was calculated using a discounted cash flow and was determined to be lower than its carrying value. As a result, the Company recorded a $ 10.0 million impairment charge to write down the value of the partnership intangible asset to its estimated fair value. The charge was recorded within sales and marketing expenses in its Consumer and Research segment in the condensed consolidated statements of operations and comprehensive loss during the third quarter of fiscal 2023. There was no impairment to intangible assets during the three months ended June 30, 2023 and 2022. Estimated future amortization expense of the identified intangible assets as of June 30, 2023 was as follows: Estimated Amortization (in thousands) Fiscal years ending March 31, Remainder of 2024 (Remaining nine months) $ 8,423 2025 7,919 2026 7,919 2027 6,769 2028 5,006 Thereafter 5,642 Total estimated future amortization expense $ 41,678 Accrued Expense and Other Current Liabilities Accrued expense and other current liabilities consisted of the following: June 30, 2023 March 31, 2023 (in thousands) Accrued payables $ 13,132 $ 17,030 Accrued compensation and benefits 15,104 14,737 Accrued bonus 5,638 21,600 Accrued clinical expenses 14,998 11,707 Accrued taxes and other 1,343 1,356 Total accrued expenses and other current liabilities $ 50,215 $ 66,430

Restructuring

Restructuring	3 Months Ended
	Jun. 30, 2023
Restructuring and Related Activities [Abstract]
Restructuring	9. Restructuring In June 2023, the Company approved a reduction in force intended to restructure and strategically align its workforce with the Company’s strategy and to reduce the Company’s operating costs. As a result, during the three months ended June 30, 2023, the Company recorded restructuring charges of $ 4.2 million within restructuring and other charges in the condensed consolidated statements of operations, of which $ 3.6 million was related to cash severance payments and benefits continuation and $ 0.6 million was related to non-cash stock-compensation charges associated with the modification of certain stock awards. The restructuring charges were primarily related to the Consumer and Research Services segment. The following table shows the total amount incurred and accrued related to one-time employee termination benefits: One-Time Employee Termination Benefits (in thousands) Accrued restructuring costs included in accrued expenses and other current liabilities as of March 31, 2023 $ — Restructuring charges incurred during the period 4,217 Amounts paid during the period ( 3,290 ) Accrued restructuring costs included in accrued expenses and other current liabilities as of June 30, 2023 $ 927 The Company does not expect to incur any further material expenses in connection with the reduction in force event that occurred on June 9, 2023.

Leases

Leases	3 Months Ended
	Jun. 30, 2023
Leases [Abstract]
Leases	10. Leases The Company has entered into operating leases for its corporate offices, lab facilities, and storage spaces, with remaining contractual periods ranging from 2.5 years to 8.1 years. For the Company’s facility in Sunnyvale, California, there is an option to extend the lease for a period of seven years. The Company is not reasonably certain that it will exercise this option and therefore it is not included in its right-of-use (“ROU”) assets and lease liabilities as of June 30, 2023. The Company did not have any finance leases for all the periods presented. For the three months ended June 30, 2023 and 2022, the Company recorded operating lease costs of $ 3.4 million and $ 3.4 million, respectively, and variable operating lease costs of $ 1.3 million and $ 1.5 million, respectively. As of June 30, 2023, the future minimum lease payments included in the measurement of the Company’s operating lease liabilities were as follows: June 30, (in thousands) Fiscal years ending March 31, 2024 (remaining nine months) $ 10,104 2025 15,474 2026 15,946 2027 15,472 2028 11,666 Thereafter 41,430 Total future operating lease payments 110,092 Less: imputed interest ( 26,857 ) Total operating lease liabilities $ 83,235

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	11. Commitments and Contingencies Non-cancelable Purchase Obligations In the normal course of business, the Company enters into agreements containing non-cancelable purchase commitments for goods or services with various parties. As of June 30, 2023, the Company had a total of $ 29.5 million in outstanding non-cancelable purchase obligations with a term of 12 months or longer. Legal Matters The Company is subject to certain routine legal and regulatory proceedings, as well as demands and claims that arise in the normal course of business. Certain conditions may exist as of the date that the consolidated financial statements are issued, which may result in a loss to the Company, but will only be recorded when one or more future events occur or fail to occur. The Company’s management assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against and by the Company or unasserted claims that may result in such proceedings, the Company’s management evaluates the perceived merits of any legal proceedings or unasserted claims, as well as the perceived merits of the amount of relief sought or expected to be sought. Management is not currently aware of any matters that are reasonably likely to have a material adverse impact on the Company’s business, financial position, results of operations, or cash flows. Indemnification The Company enters into indemnification provisions under agreements with other companies in the ordinary course of business, including, but not limited to, collaborators, landlords, vendors, and contractors. Pursuant to these arrangements, the Company agrees to indemnify, defend, and hold harmless the indemnified party for certain losses suffered or incurred by the indemnified party as a result of the Company’s activities. The maximum potential amount of future payments the Company could be required to make under these agreements is not determinable. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the Company believes the fair value of these provisions is not material. The Company maintains insurance, including commercial general liability insurance and product liability insurance, to offset certain potential liabilities under these indemnification provisions. In addition, the Company indemnifies its officers, directors, and certain key employees against claims made with respect to matters that arise while they are serving in their respective capacities as such, subject to certain limitations set forth under applicable law, the Company’s Bylaws, and applicable indemnification agreements. As of June 30, 2023 , the Company did not have any indemnification claims.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Jun. 30, 2023
Equity [Abstract]
Stockholders' Equity	12. Stockholders' Equity Common Stock The Company has authorized Class A common stock and Class B common stock. The rights of the holders of Class A common stock and Class B common stock are identical, except with respect to voting and conversion rights. Holders of Class A common stock are entitled to one vote per share and holders of Class B common stock are entitled to ten votes per share. Each share of Class B common stock is convertible into one share of Class A common stock any time at the option of the holder and is automatically converted into one share of Class A common stock upon transfer (except for certain permitted transfers). Once converted into Class A common stock, the Class B common stock will not be reissued. Earn-Out Shares As of June 30, 2023 and March 31, 2023, the Class A common stock included 3,814,125 shares held by VGAC founders (“Earn-Out Shares”) that are subject to a lock-up of seven years from the Closing Date. The lock-up has an early release effective (i) with respect to 50 % of the Earn-Out Shares, upon the closing price of the Company’s Class A common stock equaling or exceeding $ 12.50 per share for any 20 trading days within any 30 -trading-day period, and (ii) with respect to the other 50 % of the Earn-Out Shares, upon the closing price of the Company’s Class A common stock equaling or exceeding $ 15.00 per share for any 20 trading days within any 30 -trading-day period; provided that the transfer restrictions applicable to the Earn-Out Shares will terminate on the date following the closing date on which the Company completes a liquidation, merger, amalgamation, capital stock exchange, reorganization, or other similar transaction that results in all of the Company’s public stockholders having the right to exchange their shares of Class A common stock for cash, securities, or other property (a “Liquidation Event”), if such Liquidation Event occurs prior to the date that the stock price thresholds referenced in (i) and (ii) are met. As of June 30, 2023, the Company did not meet any earn out thresholds. The Earn-Out Shares are issued and outstanding Class A common shares that cannot be forfeited, and as such meet the criteria for equity classification in accordance with ASC 505, Equity . Reserve for Issuance The Company has the following shares of Class A common stock reserved for future issuance, on an as-if-converted basis: June 30, March 31, 2023 2023 Outstanding stock options 68,386,690 68,050,752 Outstanding restricted stock units 42,629,558 26,562,566 Remaining shares available for future issuance under 2021 Incentive Equity Plan 28,640,341 55,922,182 Remaining shares available for future issuance under Employee Stock Purchase Plan 16,349,302 16,349,302 Total shares of common stock reserved 156,005,891 166,884,802 At-the-Market (“ATM”) Offering On February 6, 2 023, the Company filed a shelf Registration Statement on Form S-3 with the SEC, relating to the sale, from time to time, in one or more transactions, of up to $ 500 million of common stock, preferred stock, debt securities, and units (the “Shelf Registration Statement”). Also, on February 6, 2 023, the Company entered into a Sales Agreement (the “Sales Agreement”) with Cowen and Company, LLC (“Cowen” or the “Agent”), pursuant to which the Company may sell through the Agent, as the Company’s sales agent, from time to time, at the Company’s option, up to $ 150 million in aggregate principal amount of an indeterminate amount of shares (the “ATM Shares”) of the Company’s Class A common stock. Subject to the terms of the Sales Agreement, the Agent will use reasonable efforts to sell the ATM Shares from time to time, based upon the Company’s instructions (including any price, time, or size limits or other customary parameters or conditions the Company may impose), by methods deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, and pursuant to, and only upon the effectiveness of, the Shelf Registration Statement. The Company will pay the Agent a commission of 3.0 % of the gross proceeds from the sales of the ATM Shares, if any. The Company has also agreed to provide the Agent with customary indemnification and contribution rights. The offering of the ATM Shares will terminate upon the earliest of (a) the sale of the maximum number or amount of the ATM Shares permitted to be sold under the Sales Agreement and (b) the termination of the Sales Agreement by the parties thereto. While the Company cannot provide any assurances that it will sell any ATM Shares pursuant to the Sales Agreement, the Company expects to use the net proceeds from the sale of securities under the Sales Agreement, if any, for general corporate purposes, including working capital requirements and operating expenses; the Company, however, has not allocated the net proceeds for specific purposes. As of June 30, 2023 , the Company has not made any sales under the Sales Agreement.

Equity Incentive Plans and Stoc

Equity Incentive Plans and Stock-Based Compensation	3 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Equity Incentive Plans and Stock-Based Compensation	13. Equity Incentive Plans and Stock-Based Compensation Incentive Equity Plans In 2006, 23andMe, Inc. established its 2006 Equity Incentive Plan, as amended (the “2006 Plan”), which provided for the grant of stock options and restricted stock to its employees, directors, officers, and consultants. The 2006 Plan allowed for time-based or performance-based vesting for the awards. The 2006 Plan was amended and restated at various times since its adoption. On June 10, 2021, the shareholders of VGAC approved the 23andMe Holding Co. 2021 Incentive Equity Plan (the “2021 Plan”) and reserved 136,000,000 authorized shares of the Company’s Class A common stock for issuance thereunder. In addition, all equity awards of 23andMe, Inc. that were issued under the 2006 Plan were converted into comparable equity awards that are settled or exercisable for shares of the Company’s Class A common stock. As a result, each 23andMe, Inc. stock option was converted into an option to purchase shares of the Company’s Class A common stock based on an exchange ratio of 2.293698169 . As of the effective date of the 2021 Plan, no further stock awards have been or will be granted under the 2006 Plan. The 2021 Plan authorizes the issuance or transfer of up to 136,000,000 shares of Class A common stock. The number of shares of Class A common stock reserved for issuance under the 2021 Plan will automatically increase on January 1 of each calendar year, starting in 2022, in an amount equal to (i) 22,839,019 shares of Class A common stock, (ii) 3.0 % of the aggregate number of shares of Class A common stock and Class B common stock outstanding, or (iii) a lesser number of shares determined by the Company’s Board of Directors prior to the applicable January 1. In November 2021, in connection with the Lemonaid Acquisition, the Company registered an additional 2,990,386 shares of Class A common stock issuable under the 2021 Plan, which represent shares of Class A common stock issuable in exchange for outstanding options initially granted under Lemonaid Health’s 2014 Equity Incentive Plan, as amended. As of June 30, 2023, 139,656,589 shares of the Company’s Class A common stock remained available for future issuance under the 2021 Plan. Options under the 2021 Plan have a contractual life of up to ten years . The exercise price of a stock option shall not be less than 100 % of the estimated fair value of the shares on the date of grant, as determined by the Board of Directors. For Incentive Stock Options (“ISO”) as defined in the Internal Revenue Code of 1986, as amended (the “Code”), the exercise price of an ISO granted to a 10 % stockholder shall not be less than 110 % of the estimated fair value of the underlying stock on the date of grant as determined by the Board of Directors. The Company’s options generally vest over three to four years . Under the 2021 Plan, stock option awards entitle the holder to receive one share of Class A common stock for every option exercised. Under the 2006 Plan and 2021 Plan, restricted stock units (“RSUs”) may be granted to employees, non-employee directors and consultants. The RSUs vest ratably over a period ranging from one to four years and are subject to the participant’s continuing service to the Company over that period. Until vested, RSUs do not have the voting and dividend participation rights of common stock and the shares underlying the awards are not considered issued and outstanding. In February 2022, the Compensation Committee of the Company’s Board of Directors adopted a RSU conversion and deferral program for non-employee directors. The purpose of the program is to provide non-employee directors with the option to convert all or a portion of their cash compensation into a RSU award under the 2021 Plan and the opportunity to defer settlement of all or a portion of their RSU awards. As of June 30, 2023, four non-employee directors had elected to convert all of their cash compensation into RSU awards, and two non-employee directors had elected to defer settlement of their RSU awards under the program. On June 9, 2022, the Compensation Committee of the Company’s Board of Directors adopted an Annual Incentive Plan (the “2022 AIP”), pursuant to which, beginning in fiscal 2023, which began on April 1, 2022, employees and certain service providers of 23andMe, Inc. and its affiliates were eligible to receive annual incentive bonuses in the form of cash or RSUs issued by the Company under the 2021 Plan, based upon the Company’s achievement of certain pre-established financial, operational, and strategic performance metrics. On June 5, 2023, the fiscal 2023 annual incentive bonuses were paid in the form of RSUs based upon the Company’s achievement of certain pre-established financial, operational, and strategic performance metrics and as determined by the Compensation Committee of the Company’s Board of Directors. The number of RSUs granted was determined by dividing the dollar amount of the 2022 AIP annual incentive bonuses for fiscal 2023 by the trailing average closing price of the Company’s Class A common stock for the 20 days preceding the date of payment, resulting in the grant of 8,961,053 shares underlying fully-vested RSUs. The Company accounts for the RSUs issued under the 2022 AIP (the “2022 AIP RSUs”) as liability awards, and adjusts the liability and corresponding expenses at the end of each quarter until the date of settlement, considering the probability that the performance conditions will be satisfied. The Company recorded stock-based compensation expense of $ 4.4 million and $ 5.0 million related to the 2022 AIP RSUs for the three months ended June 30, 2023 and 2022, respectively. As of June 30, 2023 and March 31, 2023, the liability of the 2022 AIP RSUs was $ 5.5 million and $ 18.9 million, respectively, which was included in other current liabilities on the condensed consolidated balance sheet. Stock Option Activity Stock option activity and activity regarding shares available for grant under the 2021 Plan are as follows: Options Outstanding Outstanding Weighted-Average Weighted-Average Aggregate (in thousands, except share, years, and per share data) Balance as of March 31, 2023 68,050,752 $ 4.20 6.0 $ 10,621 Granted 2,018,253 $ 2.06 Exercised ( 180,718 ) $ 0.48 Canceled/forfeited/expired ( 1,501,597 ) $ 5.67 Balance as of June 30, 2023 68,386,690 $ 4.12 5.7 $ 7,121 Vested and exercisable as of June 30, 2023 49,302,828 $ 4.16 4.8 $ 5,402 The weighted average grant date fair value per share of options granted for the three months ended June 30, 2023 and 2022 was $ 1.43 and $ 2.44 , respectively. The total intrinsic value of vested options exercised for the three months ended June 30, 2023 and 2022 was $ 0.2 million and $ 1.5 million, respectively. As of June 30, 2023, unrecognized stock-based compensation expense related to unvested stock options was $ 57.9 million, which is expected to be recognized over a weighted-average period of 2.4 years. Due to a valuation allowance on deferred tax assets, the Company did no t recognize any tax benefit from stock option exercises for the three months ended June 30, 2023 and 2022. The Company estimated the fair value of options granted using the Black-Scholes option-pricing model. The fair value of stock options is being amortized on a straight-line basis over the requisite service period of the awards. The weighted average Black-Scholes assumptions used to value stock options at the grant dates are as follows: Three Months Ended June 30, 2023 2022 Min Max Min Max Expected term (years) 5.8 6.0 6.0 6.8 Expected volatility 78 % 79 % 76 % 77 % Risk-free interest rate 3.6 % 3.9 % 2.8 % 2.8 % Expected dividend yield — — — — Restricted Stock Units The following table summarizes the RSU activity under the equity incentive plans and related information: Unvested RSUs Weighted-Average Balance as of March 31, 2023 26,562,566 $ 4.73 Granted 30,076,226 $ 2.15 Vested ( 10,757,178 ) $ 2.64 Canceled/forfeited ( 3,252,056 ) $ 4.00 Balance as of June 30, 2023 42,629,558 $ 3.49 As of June 30, 2023, unrecognized stock-based compensation expense related to outstanding unvested RSUs was $ 136.3 million, which is expected to be recognized over a weighted-average period of 2.9 years. Stock Subject to Vesting In November 2021, in connection with the Lemonaid Acquisition, the Company granted 3,747,027 shares of Class A common stock with an aggregate grant date fair value of $ 43.9 million to two recipients, each of whom was a former stockholder and officer of Lemonaid Health (each, a “Former Lemonaid Officer”) and each of whom, following the closing of the Lemonaid Acquisition, joined the Company’s management team. The shares vest over a four-year period in quarterly installments beginning on February 1, 2022, subject to the respective recipient’s continued employment with the Company. In connection with the Lemonaid Acquisition, each of these recipients entered into a relinquishment agreement that provides that during the four-year period that commenced on November 1, 2021 (the “Protection Period”), the Company will not (i) terminate the recipient’s employment without cause, (ii) materially reduce the recipient’s base salary or the benefits to which similarly-situated executive employees of the Company or the Company’s subsidiaries are entitled, other than a broad-based reduction to the same extent that applies to such similarly-situated executive employees, or (iii) relocate the recipient’s principal place of employment to a location outside of a 50-mile radius of their current principal place of employment. If any such event occurs during the Protection Period or in the event of recipient’s death or disability, then the unvested portion(s) of these awards will immediately vest. The employment of one of the Former Lemonaid Officers terminated as of June 30, 2023, which resulted in $ 22.0 million of related stock-based compensation expense recognized within general and administrative expenses within the condensed consolidated statement of operations for the three months ended June 30, 2023. The Company recognized total stock-based compensation expense related to these awards of $ 24.7 million and $ 2.7 million for the three months ended June 30, 2023 and 2022, respectively, within general and administrative expenses. Unrecognized stock-based compensation expense of $ 3.7 million for the remaining recipient is expected to be recognized over a weighted average period of 2.3 years. Employee Stock Purchase Plan On June 10, 2021, the shareholders of VGAC approved the 23andMe Holding Co. Employee Stock Purchase Plan (“ESPP”). A total of 11,420,000 shares of the Company’s Class A common stock were initially reserved for issuance under the ESPP. Pursuant to the terms of the ESPP, the number of shares of the Company’s Class A common stock reserved for issuance will automatically increase on January 1 of each calendar year, beginning on January 1, 2023, by the lesser of (i) an amount equal to one percent ( 1.0 %) of the total number of shares of Class A and Class B common stock outstanding as of the last day of the immediately preceding December 31st, (ii) 5,000,000 shares, or (iii) a lesser number of shares as determined by the Board of Directors in its discretion. As of June 30, 2023, 2,642,313 shares of the Company’s Class A common stock have been issued and 16,349,302 shares remained available for future issuance under the ESPP. The ESPP provides for concurrent 12-month offerings with successive six-month purchase intervals commencing on March 1 and September 1 of each year and purchase dates occurring on the last day of each such purchase interval (i.e., August 31 and February 28). The ESPP contains a rollover provision whereby if the price of the Company’s Class A common stock on the first day of a new offering period is less than the price on the first day of any preceding offering period, all participants in a preceding offering period with a higher first day price will be automatically withdrawn from such preceding offering period and re-enrolled in the new offering period. The rollover feature, when triggered, will be accounted for as a modification to the preceding offering period, resulting in incremental expense to be recognized over the new offering period. There were no offering dates during the three months ended June 30, 2023 and 2022. Stock-Based Compensation Total stock-based compensation expense, including stock-based compensation expense related to awards classified as liabilities, was included in costs and expenses as follows: Three Months Ended June 30, 2023 2022 (in thousands) Cost of revenue $ 2,472 $ 3,327 Research and development 11,692 12,076 Sales and marketing 1,718 2,889 General and administrative (1) 34,576 12,170 Restructuring and other charges 642 — Total stock-based compensation expense $ 51,100 $ 30,462 (1) Includes $ 22.0 million of stock-based compensation expense related to the termination of a Former Lemonaid Officer d uring the three months ended June 30, 2023.

Income Taxes

Income Taxes	3 Months Ended
	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Income Taxes	16. Income Taxes The Company computes the provision for income taxes by applying the estimated annual effective tax rate to year-to-date income from recurring operations and adjusts the provision for discrete tax items recorded in the period. The Company’s annual estimated effective tax rate differs from the U.S. federal statutory rate primarily as a result of a valuation allowance against its deferred tax assets. There was no income tax expense or benefit recognized for the three months ended June 30, 2023. A $ 0.3 million tax benefit was recognized for the three months ended June 30, 2022 and is reflected on the condensed consolidated statements of operations and comprehensive loss for the period. The Company continues to maintain a full valuation allowance on the remaining net deferred tax assets of the U.S. entities as it is more likely than not that the Company will not realize the deferred tax assets. Utilization of net operating loss carryforwards may be subject to future annual limitations provided by Section 382 of the Code and similar state provisions. The Company files income tax returns in the U.S. federal jurisdiction, various states, and the U.K. The Company is not currently under examination by income tax authorities in federal, state, or other jurisdictions. All tax returns will remain open for examination by the federal and state authorities for three and four years, respectively, from the date of utilization of any net operating loss or credits.

Retirement Benefit Plans

Retirement Benefit Plans	3 Months Ended
	Jun. 30, 2023
Retirement Benefits [Abstract]
Retirement Benefit Plans	15. Retirement Benefit Plans The Company has established a 401(k) retirement plan that allows participating employees in the U.S. to contribute as defined by the plan and is subject to limitations under Section 401(k) of the Code. The Company matches the greater of 100 % of the first 2 % or 100 % of the first $ 2,300 (subject to annual compensation and contribution limits) of employee contributions. The Company recognized matching contributions cost of $ 0.9 million and $ 0.6 million for the three months ended June 30, 2023 and 2022 , respectively.

Net Loss Per Share Attributable

Net Loss Per Share Attributable to Common Stockholders	3 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Net Loss Per Share Attributable to Common Stockholders	14. Net Loss Per Share Attributable to Common Stockholders The net loss attributable to common stockholders is allocated on a proportionate basis, and the resulting net loss per share is identical for Class A and Class B common stock under the two-class method. No di vidends were declared or paid for the three months ended June 30, 2023 and 2022. The Company’s stock options, RSUs, restricted stock awards subject to vesting and estimated shares to be issued under the ESPP plan are considered to be potential common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common stockholders as their effect is anti-dilutive. Net loss attributable to common stockholders was equivalent to net loss for all periods presented. The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders for the periods presented: Three Months Ended June 30, 2023 2022 Class A Class B Class A Class B (in thousands, except share and per share data) Numerator: Net loss attributable to common stockholders $ ( 66,563 ) $ ( 38,061 ) $ ( 48,584 ) $ ( 40,948 ) Denominator: Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 294,089,562 168,164,880 242,292,436 204,212,893 Net loss per share attributable to common stockholders: Net loss per share attributable to common stockholders, basic and diluted $ ( 0.23 ) $ ( 0.23 ) $ ( 0.20 ) $ ( 0.20 ) The potential shares of Class A common stock that were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been anti-dilutive were as follows: Three Months Ended June 30, 2023 2022 Outstanding stock options 68,386,690 71,980,548 Restricted stock units 42,629,558 23,076,570 Shares subject to vesting 334,794 3,278,650 ESPP 2,776,927 3,456,238 Total 114,127,969 101,792,006 There were no potential shares of Class B common stock that were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented.

Subsequent Events

Subsequent Events	3 Months Ended
	Jun. 30, 2023
Subsequent Events [Abstract]
Subsequent Events	17. Subsequent Events On July 10, 2023, the Company entered into a definitive agreement to sell Lemonaid Health Limited, its wholly-owned, indirect U.K. subsidiary. The transaction closed on August 1, 2023 and is not expected to have a material effect on the Company's consolidated financial statements. On August 8, 2023, the Company approved a reduction in force primarily related to its Therapeutics segment. The reduction in force is intended to restructure and strategically align the Therapeutics’ workforce with the Company’s current strategy. The Company expects to complete the reduction plan substantially during the second quarter of its fiscal 2024, with certain affected employees retained through a transition period. The Company expects to recognize restructuring charges in connection with the workforce reduction plan with respect to severance payments, benefits continuation, and stock compensation charges associated with the modification of certain stock options and restricted stock units. Severance and benefit continuation charges are estimated to be approximately $ 3.0 million and are expected to be recognized primarily in the second quarter of fiscal 2024, with the majority of such charges anticipated to be paid in cash during the same quarter. Stock compensation charges are expected to be approximately $ 0.8 million and are expected to be recognized primarily in the second quarter of fiscal 2024, and will not result in any cash expenditures.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation and Principle of Consolidation	Basis of Presentation and Principle of Consolidation The Company’s unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and include the accounts of the Company and its wholly owned subsidiaries, and variable interest entities in which it holds a controlling financial interest. All intercompany accounts and transactions have been eliminated in consolidation. For the three months ended June 30, 2023 and 2022, the Company’s operations were primarily in the United States, with immaterial operations in the United Kingdom (“U.K.”). There have been no material changes to the Company's significant accounting policies for the three months ended June 30, 2023 , as compared to the audited consolidated financial statements in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2023.
Unaudited Interim Condensed Consolidated Financial Information	Unaudited Interim Condensed Consolidated Financial Information The accompanying interim condensed consolidated financial statements as of June 30, 2023 and for the three months ended June 30, 2023 and 2022 and accompanying notes, are unaudited. These unaudited interim condensed consolidated financial statements (the “condensed consolidated financial statements”) have been prepared in accordance with GAAP applicable to interim financial statements. These financial statements are presented in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) and do not include all disclosures normally required in annual consolidated financial statements prepared in accordance with GAAP. As such, the information included herein should be read in conjunction with the consolidated financial statements and accompanying notes as of and for the fiscal year ended March 31, 2023 (the “audited consolidated financial statements”) that were included in the Company’s Annual Report on Form 10-K filed with the SEC on May 25, 2023. In management’s opinion, the unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements, which include only normal recurring adjustments, necessary for a fair statement of the Company’s financial position as of June 30, 2023 and its condensed consolidated results of operations and cash flows for the three months ended June 30, 2023 and 2022. The results of operations for the three months ended June 30, 2023 are not necessarily indicative of the results expected for the year ending March 31, 2024 or any other future interim or annual periods.
Fiscal Year	Fiscal Year The Company’s fiscal year ends on March 31. References to fiscal 2024 refer to the fiscal year ending March 31, 2024 and references to fiscal 2023 and fiscal 2022 refer to the fiscal years ended March 31, 2023 and March 31, 2022, respectively.
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities and the related disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period and the accompanying notes. Significant items subject to such estimates and assumptions include, but are not limited to the determination of standalone selling price for various performance obligations; the estimated expected benefit period for the rate and recognition pattern of breakage revenue for purchases where a saliva collection kit (“Kit”) is never returned for processing; the capitalization and estimated useful life of internal use software; the useful life of long-lived assets; fair value of intangible assets acquired in business combinations; the carrying value of goodwill; the incremental borrowing rate for operating leases; stock-based compensation including the determination of the fair value of stock options, annual incentive bonuses payable in the form of restricted stock units (“RSUs”), as well as the Company’s common stock prior to the Closing Date of the Merger; and the valuation of deferred tax assets and uncertain tax positions. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that it believes are reasonable under the circumstances, including assumptions as to future events. Actual results could differ from these estimates, and such differences could be material to the condensed consolidated financial statements. The Company is not aware of any specific event or circumstance that would require revisions to estimates, updates to judgments, or adjustments to the carrying value of assets or liabilities. These estimates may change, as new events occur and additional information is obtained, and will be recognized in the condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the condensed consolidated financial statements.
Concentration of Supplier Risk	Concentration of Supplier Risk Certain of the raw materials, components and equipment associated with the deoxyribonucleic acid (“DNA”) microarrays and Kits used by the Company in the delivery of its services are available only from third-party suppliers. The Company also relies on a third-party laboratory service for the processing of its customer samples. Shortages and slowdowns could occur in these essential materials, components, equipment, and laboratory services due to an interruption of supply or increased demand in the industry. If the Company were unable to procure certain materials, components, equipment, or laboratory services at acceptable prices, it would be required to reduce its laboratory operations, which could have a material adverse effect on its results of operations. A single supplier accounted for 100 % of the Company’s total purchases of microarrays and a separate single supplier accounted for 100 % of the Company’s total purchases of Kits for the three months ended June 30, 2023 and 2022 . One laboratory service provider accounted for 100 % of the Company’s processing of customer samples for the three months ended June 30, 2023 and 2022 .
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk include cash, cash equivalents and accounts receivable. The Company maintains a majority of its cash and cash equivalents with a single high-quality financial institution, the composition and maturities of which are regularly monitored by the Company. The Company’s revenue and accounts receivable are derived primarily from the United States. See Note 3, “ Revenue, ” for additional information regarding geographical disaggregation of revenue. The Company grants credit to its customers in the normal course of business, performs ongoing credit evaluations of its customers, and does not require collateral. The Company regularly monitors the aging of accounts receivable balances. Significant customer information is as follows: June 30, March 31, Percentage of accounts receivable: Customer C (1) 66 % 69 % Customer F * 27 % Customer G 12 % * Customer H 12 % * * less than 10% (1) Customer C is a reseller. Three Months Ended June 30, 2023 2022 Percentage of revenue: Customer C (1) 16 % 15 % Customer B 18 % 13 % (1) Customer C is a reseller.
Restructuring Expense	Restructuring The Company defines restructuring expenses to include costs directly associated with exit or disposal activities, such as severance payments, benefits continuation, and non-cash stock-compensation charges associated with the modification of certain stock awards. In general, the Company records involuntary employee-related exit and disposal costs when it communicates to employees that they are entitled to receive such benefits and the amount can be reasonably estimated.
Liquidity	Liquidity The Company’s operations have been financed primarily through the sales of equity securities and revenue from sales of PGS, telehealth, and research services. During fiscal 2022, the Company received gross proceeds of $ 309.7 million from the Merger and $ 250.0 million from the PIPE investment consummated in connection with the Merger. The Company expects to continue to incur operating losses and negative cash flows from operations for the foreseeable future due to the investments it intends to continue to make in research and development, along with general and administrative, and sales and marketing, expenses incurred to capitalize on market opportunities and drive long-term growth. The Company may require additional financing to fund operations to meet its business plan. As of June 30, 2023, the Company had cash and cash equivalents of $ 314.4 million. Based on current cash resources and the implementation of a previously-disclosed reduction in force in June 2023, the Company believes its cash and cash equivalents will be sufficient to fund estimated operating expenses and capital expenditure requirements for at least 12 months from the date of the issuance of these condensed consolidated financial statements. Management considers that there are no conditions or events in the aggregate that raise substantial doubt about the Company’s ability to continue as a going concern for a period of at least one year from the date the condensed consolidated financial statements are issued.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Summary of Significant Customer Information	Significant customer information is as follows: June 30, March 31, Percentage of accounts receivable: Customer C (1) 66 % 69 % Customer F * 27 % Customer G 12 % * Customer H 12 % * * less than 10% (1) Customer C is a reseller. Three Months Ended June 30, 2023 2022 Percentage of revenue: Customer C (1) 16 % 15 % Customer B 18 % 13 % (1) Customer C is a reseller.

Revenue (Tables)

Revenue (Tables)	3 Months Ended
	Jun. 30, 2023
Disaggregation of Revenue [Abstract]
Summary of Revenue By Category	The following table presents revenue by category: Three Months Ended June 30, 2023 2022 Amount % of Revenue Amount % of Revenue (in thousands, except percentages) Point in Time PGS $ 31,759 52 % $ 39,691 61 % Telehealth 8,285 14 % 9,361 15 % Consumer services 40,044 66 % 49,052 76 % Research services 2,353 3 % — 0 % Total $ 42,397 69 % $ 49,052 76 % Over Time PGS $ 5,270 9 % $ 4,484 7 % Telehealth 2,238 4 % 2,523 4 % Consumer services 7,508 13 % 7,007 11 % Research services 10,959 18 % 8,454 13 % Total $ 18,467 31 % $ 15,461 24 % Revenue by Category PGS $ 37,029 61 % $ 44,175 68 % Telehealth 10,523 18 % 11,884 19 % Consumer services 47,552 79 % 56,059 87 % Research services 13,312 21 % 8,454 13 % Total $ 60,864 100 % $ 64,513 100 %
Summary of Revenue by Region based on the Shipping Address of Customers	The following table summarizes revenue by region based on the shipping address of customers or the location where the services are delivered: Three Months Ended June 30, 2023 2022 Amount % of Revenue Amount % of Revenue (in thousands, except percentages) United States $ 43,326 71 % $ 48,108 75 % United Kingdom 14,355 24 % 11,975 19 % Canada 2,170 3 % 3,039 4 % Other regions 1,013 2 % 1,391 2 % Total $ 60,864 100 % $ 64,513 100 %

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis	The following table presents information about the Company’s financial instruments that are measured at fair value on a recurring basis as of June 30, 2023 and March 31, 2023: June 30, 2023 March 31, 2023 Fair Value Level 1 Level 2 Level 3 Fair Value Level 1 Level 2 Level 3 (in thousands) Financial Assets: Money market funds $ 305,500 $ 305,500 $ — $ — $ 372,000 $ 372,000 $ — $ — Total financial assets $ 305,500 $ 305,500 $ — $ — $ 372,000 $ 372,000 $ — $ —

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Jun. 30, 2023
Segment Reporting [Abstract]
Schedule Of Company Revenue and Adjusted EBITDA by Segment	The Company’s revenue and Adjusted EBITDA by segment is as follows: Three Months Ended June 30, 2023 2022 (in thousands) Segment Revenue: (1) Consumer and Research Services $ 60,864 $ 64,513 Total revenue $ 60,864 $ 64,513 Segment Adjusted EBITDA: Consumer and Research Services Adjusted EBITDA $ ( 5,602 ) $ ( 16,997 ) Therapeutics Adjusted EBITDA ( 31,138 ) ( 18,465 ) Unallocated Corporate (2) ( 13,060 ) ( 14,253 ) Total Adjusted EBITDA $ ( 49,800 ) $ ( 49,715 ) Reconciliation of net loss to Adjusted EBITDA: Net loss $ ( 104,624 ) $ ( 89,532 ) Adjustments: Interest income, net ( 4,307 ) ( 245 ) Other (income) expense, net ( 333 ) 435 Income tax benefit — ( 254 ) Depreciation and amortization 4,478 5,104 Amortization of acquired intangible assets 3,638 4,315 Stock-based compensation expense 51,100 30,462 Transaction-related costs (3) 248 — Total Adjusted EBITDA $ ( 49,800 ) $ ( 49,715 ) (1) There was no Therapeutics revenue for the three months ended June 30, 2023 and 2022. (2) Certain department expenses such as Finance, Legal, Regulatory and Supplier Quality, Corporate Communications, Corporate Development, and CEO Office are not reported as part of the reporting segments as reviewed by the CODM. These amounts are included in Unallocated Corporate. (3) Refer to Note 17, “ Subsequent Events ” for additional information .
Summary of Customers Accounting for 10% or More of Segment Revenues	Customers accounting for 10% or more of segment revenues were as follows: Three Months Ended June 30, 2023 2022 (in thousands) Consumer and Research Services Segment Revenue: Customer C (1) (2) $ 9,711 16 % $ 9,628 15 % Customer B (3) $ 10,670 18 % $ 8,246 13 % (1) Customer C is a reseller. (2) Customer C revenues are primarily in the United States. (3) Customer B revenues are in the U.K.

Balance Sheet Components (Table

Balance Sheet Components (Tables)	3 Months Ended
	Jun. 30, 2023
Balance Sheet Related Disclosures [Abstract]
Property and Equipment, Net	Property and equipment, net consisted of the following: June 30, 2023 March 31, 2023 (in thousands) Computer and software $ 10,015 $ 10,376 Laboratory equipment and software 52,689 52,785 Furniture and office equipment 8,953 8,946 Leasehold improvements 40,955 40,964 Capitalized asset retirement obligations 853 853 Property and equipment, gross 113,465 113,924 Less: accumulated depreciation and amortization ( 77,761 ) ( 75,316 ) Property and equipment, net $ 35,704 $ 38,608
Schedule of internal use software	Internal-use software, net consisted of the following: June 30, 2023 March 31, 2023 (in thousands) Capitalized internal-use software $ 28,649 $ 25,180 Less: accumulated amortization ( 10,767 ) ( 9,519 ) Internal-use software, net $ 17,882 $ 15,661
Summary of Intangible Assets, Net	Intangible assets, net consisted of the following: June 30, 2023 Weighted Average Remaining Useful Life Gross Carrying Amount Accumulated Amortization Net Carrying Amount (in thousands, except years) Customer relationships 0.3 $ 14,900 $ ( 12,417 ) $ 2,483 Partnerships 8.3 9,000 ( 1,500 ) 7,500 Trademark 3.3 11,000 ( 3,666 ) 7,334 Developed technology 5.3 24,100 ( 5,738 ) 18,362 Non-compete agreements 3.3 2,800 ( 933 ) 1,867 Patents 5.2 5,500 ( 1,368 ) 4,132 Total intangible assets $ 67,300 $ ( 25,622 ) $ 41,678 March 31, 2023 Weighted Average Remaining Useful Life Gross Carrying Amount Accumulated Amortization Cumulative Impairment Charge Cumulative Currency Translation Net Carrying Amount (in thousands, except years) Customer relationships 0.6 $ 14,900 $ ( 10,554 ) $ — $ — $ 4,346 Partnerships 8.6 23,200 ( 4,385 ) ( 9,968 ) ( 1,122 ) 7,725 Trademark 3.6 11,000 ( 3,117 ) — — 7,883 Developed technology 5.6 24,100 ( 4,877 ) — — 19,223 Non-compete agreements 3.6 2,800 ( 793 ) — — 2,007 Patents 5.5 5,500 ( 1,164 ) — — 4,336 Total intangible assets $ 81,500 $ ( 24,890 ) $ ( 9,968 ) $ ( 1,122 ) $ 45,520
Summary of Future Amortization of Intangible Assets	Estimated future amortization expense of the identified intangible assets as of June 30, 2023 was as follows: Estimated Amortization (in thousands) Fiscal years ending March 31, Remainder of 2024 (Remaining nine months) $ 8,423 2025 7,919 2026 7,919 2027 6,769 2028 5,006 Thereafter 5,642 Total estimated future amortization expense $ 41,678
Schedule of Accrued Expense and Other Current Liabilities	Accrued expense and other current liabilities consisted of the following: June 30, 2023 March 31, 2023 (in thousands) Accrued payables $ 13,132 $ 17,030 Accrued compensation and benefits 15,104 14,737 Accrued bonus 5,638 21,600 Accrued clinical expenses 14,998 11,707 Accrued taxes and other 1,343 1,356 Total accrued expenses and other current liabilities $ 50,215 $ 66,430

Restructuring (Tables)

Restructuring (Tables)	3 Months Ended
	Jun. 30, 2023
Restructuring and Related Activities [Abstract]
Schedule of Restructuring and Related Costs	The following table shows the total amount incurred and accrued related to one-time employee termination benefits: One-Time Employee Termination Benefits (in thousands) Accrued restructuring costs included in accrued expenses and other current liabilities as of March 31, 2023 $ — Restructuring charges incurred during the period 4,217 Amounts paid during the period ( 3,290 ) Accrued restructuring costs included in accrued expenses and other current liabilities as of June 30, 2023 $ 927 The Company does not expect to incur any further material expenses in connection with the reduction in force event that occurred on June 9, 2023.

Leases (Tables)

Leases (Tables)	3 Months Ended
	Jun. 30, 2023
Leases [Abstract]
Schedule of Future Minimum Lease Payments Related to Company's Operating Lease Liability	As of June 30, 2023, the future minimum lease payments included in the measurement of the Company’s operating lease liabilities were as follows: June 30, (in thousands) Fiscal years ending March 31, 2024 (remaining nine months) $ 10,104 2025 15,474 2026 15,946 2027 15,472 2028 11,666 Thereafter 41,430 Total future operating lease payments 110,092 Less: imputed interest ( 26,857 ) Total operating lease liabilities $ 83,235

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Jun. 30, 2023
Equity [Abstract]
Schedule of Common Stock Reserved for Issuance	The Company has the following shares of Class A common stock reserved for future issuance, on an as-if-converted basis: June 30, March 31, 2023 2023 Outstanding stock options 68,386,690 68,050,752 Outstanding restricted stock units 42,629,558 26,562,566 Remaining shares available for future issuance under 2021 Incentive Equity Plan 28,640,341 55,922,182 Remaining shares available for future issuance under Employee Stock Purchase Plan 16,349,302 16,349,302 Total shares of common stock reserved 156,005,891 166,884,802

Equity Incentive Plans and St_2

Equity Incentive Plans and Stock-Based Compensation (Tables)	3 Months Ended
	Jun. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Schedule of Summary of Stock Option Activity and Activity Regarding Shares Available for Grant	Stock option activity and activity regarding shares available for grant under the 2021 Plan are as follows: Options Outstanding Outstanding Weighted-Average Weighted-Average Aggregate (in thousands, except share, years, and per share data) Balance as of March 31, 2023 68,050,752 $ 4.20 6.0 $ 10,621 Granted 2,018,253 $ 2.06 Exercised ( 180,718 ) $ 0.48 Canceled/forfeited/expired ( 1,501,597 ) $ 5.67 Balance as of June 30, 2023 68,386,690 $ 4.12 5.7 $ 7,121 Vested and exercisable as of June 30, 2023 49,302,828 $ 4.16 4.8 $ 5,402
Schedule of Assumptions Used in the Black-Scholes Option-Pricing Model	The Company estimated the fair value of options granted using the Black-Scholes option-pricing model. The fair value of stock options is being amortized on a straight-line basis over the requisite service period of the awards. The weighted average Black-Scholes assumptions used to value stock options at the grant dates are as follows: Three Months Ended June 30, 2023 2022 Min Max Min Max Expected term (years) 5.8 6.0 6.0 6.8 Expected volatility 78 % 79 % 76 % 77 % Risk-free interest rate 3.6 % 3.9 % 2.8 % 2.8 % Expected dividend yield — — — —
Summary of Restricted Stock Awards Activity under the Equity Incentive Plan	The following table summarizes the RSU activity under the equity incentive plans and related information: Unvested RSUs Weighted-Average Balance as of March 31, 2023 26,562,566 $ 4.73 Granted 30,076,226 $ 2.15 Vested ( 10,757,178 ) $ 2.64 Canceled/forfeited ( 3,252,056 ) $ 4.00 Balance as of June 30, 2023 42,629,558 $ 3.49
Schedule of Share Based Compensation Costs	Total stock-based compensation expense, including stock-based compensation expense related to awards classified as liabilities, was included in costs and expenses as follows: Three Months Ended June 30, 2023 2022 (in thousands) Cost of revenue $ 2,472 $ 3,327 Research and development 11,692 12,076 Sales and marketing 1,718 2,889 General and administrative (1) 34,576 12,170 Restructuring and other charges 642 — Total stock-based compensation expense $ 51,100 $ 30,462 (1) Includes $ 22.0 million of stock-based compensation expense related to the termination of a Former Lemonaid Officer d uring the three months ended June 30, 2023.

Net Loss Per Share Attributab_2

Net Loss Per Share Attributable to Common Stockholders (Tables)	3 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders for the periods presented: Three Months Ended June 30, 2023 2022 Class A Class B Class A Class B (in thousands, except share and per share data) Numerator: Net loss attributable to common stockholders $ ( 66,563 ) $ ( 38,061 ) $ ( 48,584 ) $ ( 40,948 ) Denominator: Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 294,089,562 168,164,880 242,292,436 204,212,893 Net loss per share attributable to common stockholders: Net loss per share attributable to common stockholders, basic and diluted $ ( 0.23 ) $ ( 0.23 ) $ ( 0.20 ) $ ( 0.20 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	Three Months Ended June 30, 2023 2022 Outstanding stock options 68,386,690 71,980,548 Restricted stock units 42,629,558 23,076,570 Shares subject to vesting 334,794 3,278,650 ESPP 2,776,927 3,456,238 Total 114,127,969 101,792,006 There were no potential shares of Class B common stock that were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented.

Organization and Description _2

Organization and Description of Business - Additional Information (Detail)	3 Months Ended
	Jun. 30, 2023
Class Of Stock [Line Items]
Stockholders' Equity Note, Stock Split	Each share of Class B common stock is convertible into one share of Class A common stock any time at the option of the holder and is automatically converted into one share of Class A common stock upon transfer

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Mar. 31, 2022
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Cash and cash equivalents value	$ 314.4
Proceeds from Acquisition			$ 309.7
PIPE [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Proceeds from Acquisition			$ 250
Supplier Concentration Risk | Revenue | Microarrays
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Percentage of Revenue	100%
Supplier Concentration Risk | Revenue | K I T S
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Percentage of Revenue		100%
Supplier Concentration Risk | Revenue | Laboratory Services
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Percentage of Revenue	100%	100%

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of Significant Customer Information (Details)		3 Months Ended		12 Months Ended
		Jun. 30, 2023	Jun. 30, 2022	Mar. 31, 2023
Customer C
Concentration Risk [Line Items]
Percentage of accounts receivable	[1]	66%		69%
Customer F
Concentration Risk [Line Items]
Percentage of accounts receivable				27%
Customer G
Concentration Risk [Line Items]
Percentage of accounts receivable		12%
Customer H
Concentration Risk [Line Items]
Percentage of accounts receivable		12%
Customer Concentration Risk [Member] | Customer B | Revenue Benchmark [Member]
Concentration Risk [Line Items]
Percentage of Revenue		18%	13%
Customer Concentration Risk [Member] | Customer C | Revenue Benchmark [Member]
Concentration Risk [Line Items]
Percentage of Revenue	[2]	16%	15%
[1] Customer C is a reseller. Customer C is a reseller.

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Summary of Revenue by Category (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disaggregation Of Revenue [Line Items]
Revenue	$ 60,864	$ 64,513
PGS
Disaggregation Of Revenue [Line Items]
Revenue	37,029	44,175
PGS | Point in Time
Disaggregation Of Revenue [Line Items]
Revenue	31,759	39,691
PGS | Over Time
Disaggregation Of Revenue [Line Items]
Revenue	5,270	4,484
Telehealth
Disaggregation Of Revenue [Line Items]
Revenue	10,523	11,884
Telehealth | Point in Time
Disaggregation Of Revenue [Line Items]
Revenue	8,285	9,361
Telehealth | Over Time
Disaggregation Of Revenue [Line Items]
Revenue	2,238	2,523
Consumer services
Disaggregation Of Revenue [Line Items]
Revenue	47,552	56,059
Consumer services | Point in Time
Disaggregation Of Revenue [Line Items]
Revenue	40,044	49,052
Consumer services | Over Time
Disaggregation Of Revenue [Line Items]
Revenue	7,508	7,007
Research Services
Disaggregation Of Revenue [Line Items]
Revenue	10,959	8,454
Research Services | Point in Time
Disaggregation Of Revenue [Line Items]
Revenue	2,353	0
Research Services | Over Time
Disaggregation Of Revenue [Line Items]
Revenue	13,312	8,454
Service
Disaggregation Of Revenue [Line Items]
Revenue	60,864	64,513
Service | Point in Time
Disaggregation Of Revenue [Line Items]
Revenue	42,397	49,052
Service | Over Time
Disaggregation Of Revenue [Line Items]
Revenue	$ 18,467	$ 15,461
Product Concentration Risk [Member] | Revenue Benchmark [Member] | PGS
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	61%	68%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | PGS | Point in Time
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	52%	61%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | PGS | Over Time
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	9%	7%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Telehealth
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	18%	19%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Telehealth | Point in Time
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	14%	15%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Telehealth | Over Time
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	4%	4%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Consumer services
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	79%	87%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Consumer services | Point in Time
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	66%	76%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Consumer services | Over Time
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	13%	11%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Research Services
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	18%	13%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Research Services | Point in Time
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	3%	0%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Research Services | Over Time
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	21%	13%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Service
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	100%	100%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Service | Point in Time
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	69%	76%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Service | Over Time
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	31%	24%

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Summary of Revenue by Region (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disaggregation Of Revenue [Line Items]
Revenue	$ 60,864	$ 64,513
Service
Disaggregation Of Revenue [Line Items]
Revenue	$ 60,864	$ 64,513
Geographic Concentration Risk [Member] | Revenue Benchmark [Member] | Service
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	100%	100%
United States
Disaggregation Of Revenue [Line Items]
Revenue	$ 43,326	$ 48,108
United States | Geographic Concentration Risk [Member] | Revenue Benchmark [Member]
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	71%	75%
United Kingdom
Disaggregation Of Revenue [Line Items]
Revenue	$ 14,355	$ 11,975
United Kingdom | Geographic Concentration Risk [Member] | Revenue Benchmark [Member]
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	24%	19%
Canada
Disaggregation Of Revenue [Line Items]
Revenue	$ 2,170	$ 3,039
Canada | Geographic Concentration Risk [Member] | Revenue Benchmark [Member]
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	3%	4%
Other
Disaggregation Of Revenue [Line Items]
Revenue	$ 1,013	$ 1,391
Other | Geographic Concentration Risk [Member] | Revenue Benchmark [Member]
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	2%	2%

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis (Details) - Fair Value Recurring [Member] - USD ($) $ in Thousands	Jun. 30, 2023	Mar. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial assets	$ 305,500	$ 372,000
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial assets	305,500	372,000
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial assets	0	0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial assets	0	0
Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial assets	305,500	372,000
Money market funds | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial assets	305,500	372,000
Money market funds | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial assets	0	0
Money market funds | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial assets	$ 0	$ 0

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Mar. 31, 2023
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair Value Liabilities Level Two To Level One Transfers Amount	$ 0
Fair Value Recurring [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets Or Liabilities Fair Value	305,500		$ 372,000
Fair Value Nonrecurring [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Impairment charges	10,000
Impairment of intangible assets	0	$ 0
Level 1 | Fair Value Recurring [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets Or Liabilities Fair Value	305,500		372,000
Level 2 | Fair Value Recurring [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets Or Liabilities Fair Value	0		0
Level 3 [Member] | Fair Value Recurring [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets Or Liabilities Fair Value	$ 0		$ 0

Recapitalization - Additional I

Recapitalization - Additional Information (Details) - $ / shares	3 Months Ended	12 Months Ended
	Jun. 30, 2023	Mar. 31, 2023
Business Acquisition [Line Items]
Common stock, par value	$ 0.0001	$ 0.0001
VG Acquisition Sponsor LLC [Member]
Business Acquisition [Line Items]
Earn-out shares, Percentage	50%
Lockup period for shares	7 years	7 years
VG Acquisition Sponsor LLC [Member] | Maximum [Member]
Business Acquisition [Line Items]
Share Price Thresholds Release From Lock Up	$ 15
Class A Common Stock [Member]
Business Acquisition [Line Items]
Common stock, shares outstanding	304,011,272	293,020,474
Common stock, shares issued	304,011,272	293,020,474
Class A Common Stock [Member] | VG Acquisition Sponsor LLC [Member]
Business Acquisition [Line Items]
Earn-out shares, Percentage	50%
Trading days	20 days
Number of trading days after commencing	30 days
Class A Common Stock [Member] | VG Acquisition Sponsor LLC [Member] | Minimum [Member]
Business Acquisition [Line Items]
Share Price Thresholds Release From Lock Up	$ 12.50
Class B Common Stock [Member]
Business Acquisition [Line Items]
Common stock, shares outstanding	168,084,278	168,179,488
Common stock, shares issued	168,084,278	168,179,488

Acquisition - Schedule of Consi

Acquisition - Schedule of Consideration Transferred to Acquired Identifiable Assets and Assumed Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Mar. 31, 2023
Business Acquisition [Line Items]
Goodwill	$ 351,744	$ 351,744

Acquisition (Additional Informa

Acquisition (Additional Information) (Details) - USD ($) $ in Thousands		3 Months Ended
		Jun. 30, 2023	Jun. 30, 2022
Business Acquisition [Line Items]
Income tax benefit		$ 0	$ 254
Recognized revenue	[1]	60,864	64,513
Net income (loss)		(104,624)	(89,532)
Class A Common Stock [Member]
Business Acquisition [Line Items]
Net income (loss)		$ (66,563)	$ (48,584)
[1] There was no Therapeutics revenue for the three months ended June 30, 2023 and 2022.

Revenue - Summary of Revenue By

Revenue - Summary of Revenue By Category (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disaggregation of Revenue [Line Items]
Revenue	$ 60,864	$ 64,513
PGS
Disaggregation of Revenue [Line Items]
Revenue	37,029	44,175
PGS | Point in Time
Disaggregation of Revenue [Line Items]
Revenue	31,759	39,691
PGS | Over Time
Disaggregation of Revenue [Line Items]
Revenue	5,270	4,484
Telehealth
Disaggregation of Revenue [Line Items]
Revenue	10,523	11,884
Telehealth | Point in Time
Disaggregation of Revenue [Line Items]
Revenue	8,285	9,361
Telehealth | Over Time
Disaggregation of Revenue [Line Items]
Revenue	2,238	2,523
Consumer services
Disaggregation of Revenue [Line Items]
Revenue	47,552	56,059
Consumer services | Point in Time
Disaggregation of Revenue [Line Items]
Revenue	40,044	49,052
Consumer services | Over Time
Disaggregation of Revenue [Line Items]
Revenue	7,508	7,007
Research Services
Disaggregation of Revenue [Line Items]
Revenue	10,959	8,454
Research Services | Point in Time
Disaggregation of Revenue [Line Items]
Revenue	2,353	0
Research Services | Over Time
Disaggregation of Revenue [Line Items]
Revenue	13,312	8,454
Service
Disaggregation of Revenue [Line Items]
Revenue	60,864	64,513
Service | Point in Time
Disaggregation of Revenue [Line Items]
Revenue	42,397	49,052
Service | Over Time
Disaggregation of Revenue [Line Items]
Revenue	$ 18,467	$ 15,461
Product Concentration Risk | Revenue | PGS
Disaggregation of Revenue [Line Items]
Percentage of Revenue	61%	68%
Product Concentration Risk | Revenue | PGS | Point in Time
Disaggregation of Revenue [Line Items]
Percentage of Revenue	52%	61%
Product Concentration Risk | Revenue | PGS | Over Time
Disaggregation of Revenue [Line Items]
Percentage of Revenue	9%	7%
Product Concentration Risk | Revenue | Telehealth
Disaggregation of Revenue [Line Items]
Percentage of Revenue	18%	19%
Product Concentration Risk | Revenue | Telehealth | Point in Time
Disaggregation of Revenue [Line Items]
Percentage of Revenue	14%	15%
Product Concentration Risk | Revenue | Telehealth | Over Time
Disaggregation of Revenue [Line Items]
Percentage of Revenue	4%	4%
Product Concentration Risk | Revenue | Consumer services
Disaggregation of Revenue [Line Items]
Percentage of Revenue	79%	87%
Product Concentration Risk | Revenue | Consumer services | Point in Time
Disaggregation of Revenue [Line Items]
Percentage of Revenue	66%	76%
Product Concentration Risk | Revenue | Consumer services | Over Time
Disaggregation of Revenue [Line Items]
Percentage of Revenue	13%	11%
Product Concentration Risk | Revenue | Research Services
Disaggregation of Revenue [Line Items]
Percentage of Revenue	18%	13%
Product Concentration Risk | Revenue | Research Services | Point in Time
Disaggregation of Revenue [Line Items]
Percentage of Revenue	3%	0%
Product Concentration Risk | Revenue | Research Services | Over Time
Disaggregation of Revenue [Line Items]
Percentage of Revenue	21%	13%
Product Concentration Risk | Revenue | Service
Disaggregation of Revenue [Line Items]
Percentage of Revenue	100%	100%
Product Concentration Risk | Revenue | Service | Point in Time
Disaggregation of Revenue [Line Items]
Percentage of Revenue	69%	76%
Product Concentration Risk | Revenue | Service | Over Time
Disaggregation of Revenue [Line Items]
Percentage of Revenue	31%	24%

Revenue - Summary of Revenue _2

Revenue - Summary of Revenue by Region based on the Shipping Address of Customers (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disaggregation of Revenue [Line Items]
Revenue	$ 60,864	$ 64,513
Service
Disaggregation of Revenue [Line Items]
Revenue	$ 60,864	$ 64,513
Revenue | Geographic Concentration Risk | Service
Disaggregation of Revenue [Line Items]
Percentage of Revenue	100%	100%
United States
Disaggregation of Revenue [Line Items]
Revenue	$ 43,326	$ 48,108
United States | Revenue | Geographic Concentration Risk
Disaggregation of Revenue [Line Items]
Percentage of Revenue	71%	75%
United Kingdom
Disaggregation of Revenue [Line Items]
Revenue	$ 14,355	$ 11,975
United Kingdom | Revenue | Geographic Concentration Risk
Disaggregation of Revenue [Line Items]
Percentage of Revenue	24%	19%
Canada
Disaggregation of Revenue [Line Items]
Revenue	$ 2,170	$ 3,039
Canada | Revenue | Geographic Concentration Risk
Disaggregation of Revenue [Line Items]
Percentage of Revenue	3%	4%
Other
Disaggregation of Revenue [Line Items]
Revenue	$ 1,013	$ 1,391
Other | Revenue | Geographic Concentration Risk
Disaggregation of Revenue [Line Items]
Percentage of Revenue	2%	2%

Revenue (Additional Information

Revenue (Additional Information) (Details) - USD ($) $ in Millions	3 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Mar. 31, 2023
Disaggregation of Revenue [Line Items]
Breakage revenue recognized	$ 4.6	$ 5
Consumer services
Disaggregation of Revenue [Line Items]
Deferred revenue for customer services	45.9		$ 48.6
Breakage revenue recognized	22.5
Research Services
Disaggregation of Revenue [Line Items]
Deferred revenue for customer services	2.2		14
Breakage revenue recognized	12.4
Contract with customer liability revenue recognized related party amount	10.7
Contract with customer liability related party amount	1.1		$ 11.8
Remaining performance obligations	$ 3.1
Revenue recognize percentage	81%

Variable Interest Entities (Add

Variable Interest Entities (Additional Information) (Details) - USD ($) $ in Thousands		3 Months Ended
		Jun. 30, 2023	Jun. 30, 2022	Mar. 31, 2023
Aggregate carrying value of assets		$ 871,199		$ 942,598
Aggregate Carrying Value of total liabilities		195,709		$ 228,659
Recognized revenue	[1]	60,864	$ 64,513
Net loss		(104,624)	(89,532)
VIE [Member]
Recognized revenue		9,000	10,700
Net loss		$ 2,600	$ 400
[1] There was no Therapeutics revenue for the three months ended June 30, 2023 and 2022.

Segment Information - Schedule

Segment Information - Schedule of Company Revenue and Adjusted EBITDA by Segment (Details) - USD ($) $ in Thousands		3 Months Ended
		Jun. 30, 2023	Jun. 30, 2022
Segment Revenue
Recognized revenue	[1]	$ 60,864	$ 64,513
Segment Adjusted EBITDA
Total Adjusted EBITDA		(49,800)	(49,715)
Net loss		(104,624)	(89,532)
Adjustments
Interest income, net		(4,307)	(245)
Other income (expense), net		(333)	435
Income tax benefit		0	(254)
Depreciation and amortization		4,478	5,104
Amortization of acquired intangible assets		3,638	4,315
Stock-based compensation expense		51,100	30,462
Transaction-related costs	[2]	248
Total Adjusted EBITDA		(49,800)	(49,715)
Consumer And Research Services
Segment Revenue
Recognized revenue	[1]	60,864	64,513
Segment Adjusted EBITDA
Total Adjusted EBITDA		(5,602)	(16,997)
Therapeutics
Segment Adjusted EBITDA
Total Adjusted EBITDA		(31,138)	(18,465)
Unallocated Corporate [Member]
Segment Adjusted EBITDA
Total Adjusted EBITDA	[3]	$ (13,060)	$ (14,253)
[1] There was no Therapeutics revenue for the three months ended June 30, 2023 and 2022. Refer to Note 17, “ Subsequent Events ” for additional information Certain department expenses such as Finance, Legal, Regulatory and Supplier Quality, Corporate Communications, Corporate Development, and CEO Office are not reported as part of the reporting segments as reviewed by the CODM. These amounts are included in Unallocated Corporate.

Segment Information - Schedul_2

Segment Information - Schedule of Customer Accounting of Segment Revenue (Details) - USD ($) $ in Thousands		3 Months Ended
		Jun. 30, 2023	Jun. 30, 2022
Segment Reporting Information [Line Items]
Recognized revenue	[1]	$ 60,864	$ 64,513
Customer C | Consumer And Research Services | Revenue | Customer Concentration Risk [Member]
Segment Reporting Information [Line Items]
Recognized revenue	[2],[3]	$ 9,711	$ 9,628
Percentage of Revenue	[2],[3]	16%	15%
Customer B | Consumer And Research Services | Revenue | Customer Concentration Risk [Member]
Segment Reporting Information [Line Items]
Recognized revenue	[4]	$ 10,670	$ 8,246
Percentage of Revenue	[4]	18%	13%
[1] There was no Therapeutics revenue for the three months ended June 30, 2023 and 2022. Customer C is a reseller. Customer C revenues are primarily in the United States. Customer B revenues are in the U.K.

Collaborations - Additional Inf

Collaborations - Additional Information (Detail) - USD ($) $ in Thousands		3 Months Ended		12 Months Ended
	Oct. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Mar. 31, 2023
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue		$ 60,864	$ 64,513
Deferred Revenue Current		48,123		$ 62,521
Cost of Revenue		(30,184)	(39,023)
Accounts Payable and Other Accrued Liabilities, Current		50,215		66,430
G S K
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue		10,700	8,300
Aggregate Cash Consideration For Collaboration Arrangement	$ 50,000
Deferred Revenue Current		1,100		11,800
Research and development expense		3,300	3,500
Cost of Revenue		(300)	$ 200
Accounts Payable and Other Accrued Liabilities, Current		$ 9,000		$ 11,900
Voting interest percentage		20%		20.10%

Balance Sheet Components - Prop

Balance Sheet Components - Property and Equipment, Net (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Mar. 31, 2023
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 113,465	$ 113,924
Less: accumulated depreciation and amortization	(77,761)	(75,316)
Property and equipment, net	35,704	38,608
Computer and Software
Property Plant And Equipment [Line Items]
Property and equipment, gross	10,015	10,376
Laboratory Equipment and Software
Property Plant And Equipment [Line Items]
Property and equipment, gross	52,689	52,785
Furniture and Office Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	8,953	8,946
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment, gross	40,955	40,964
Capitalized Asset Retirement Obligations
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 853	$ 853

Balance Sheet Components - Addi

Balance Sheet Components - Additional Information (Details) - USD ($)	3 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Mar. 31, 2023
Property Plant And Equipment [Line Items]
Depreciation	$ 3,000,000	$ 3,800,000
Impairment to internal-use software	0	0
Impairment Charge for U.K Partnership Asset	10,000,000
Amortization Of Intangible Assets	3,800,000	4,500,000
Capitalized Computer Software, Gross	28,649,000		$ 25,180,000
Internal Use Software
Property Plant And Equipment [Line Items]
Amortization of internal use software including capitalized stock based compensation expense	1,200,000	1,200,000
Capitalized Computer Software Gross	$ 3,500,000	$ 1,900,000

Balance Sheet Components - Sche

Balance Sheet Components - Schedule of Internal Use Software, Net (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Mar. 31, 2023
Balance Sheet Related Disclosures [Abstract]
Capitalized internal-use software, gross	$ 28,649	$ 25,180
Less: accumulated amortization	(10,767)	(9,519)
Internal-use software, net	$ 17,882	$ 15,661

Balance Sheet Components - Summ

Balance Sheet Components - Summary of Intangible Assets, Net (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 30, 2023	Mar. 31, 2023
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 67,300	$ 81,500
Accumulated amortization	(25,622)	(24,890)
Cumulative Impairment Charge		(9,968)
Cumulative currency translation		(1,122)
Total estimated future amortization expense	$ 41,678	$ 45,520
Customer relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	3 months 18 days	7 months 6 days
Gross Carrying Amount	$ 14,900	$ 14,900
Accumulated amortization	(12,417)	(10,554)
Cumulative Impairment Charge		0
Cumulative currency translation		0
Total estimated future amortization expense	$ 2,483	$ 4,346
Partnerships [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	8 years 3 months 18 days	8 years 7 months 6 days
Gross Carrying Amount	$ 9,000	$ 23,200
Accumulated amortization	(1,500)	(4,385)
Cumulative Impairment Charge		(9,968)
Cumulative currency translation		(1,122)
Total estimated future amortization expense	$ 7,500	$ 7,725
Trademark [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	3 years 3 months 18 days	3 years 7 months 6 days
Gross Carrying Amount	$ 11,000	$ 11,000
Accumulated amortization	(3,666)	(3,117)
Cumulative Impairment Charge		0
Cumulative currency translation		0
Total estimated future amortization expense	$ 7,334	$ 7,883
Developed technology [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	5 years 3 months 18 days	5 years 7 months 6 days
Gross Carrying Amount	$ 24,100	$ 24,100
Accumulated amortization	(5,738)	(4,877)
Cumulative Impairment Charge		0
Cumulative currency translation		0
Total estimated future amortization expense	$ 18,362	$ 19,223
Non-compete agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	3 years 3 months 18 days	3 years 7 months 6 days
Gross Carrying Amount	$ 2,800	$ 2,800
Accumulated amortization	(933)	(793)
Cumulative Impairment Charge		0
Cumulative currency translation		0
Total estimated future amortization expense	$ 1,867	$ 2,007
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	5 years 2 months 12 days	5 years 6 months
Gross Carrying Amount	$ 5,500	$ 5,500
Accumulated amortization	(1,368)	(1,164)
Cumulative Impairment Charge		0
Cumulative currency translation		0
Total estimated future amortization expense	$ 4,132	$ 4,336

Balance Sheet Components - Su_2

Balance Sheet Components - Summary of Future Amortization of Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Remainder of 2024 (Remaining nine months)	$ 8,423
2025	7,919
2026	7,919
2027	6,769
2028	5,006
Thereafter	5,642
Total estimated future amortization expense	$ 41,678	$ 45,520

Balance Sheet Components - Sc_2

Balance Sheet Components - Schedule of Accrued Expense and Other Current Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Mar. 31, 2023
Balance Sheet Related Disclosures [Abstract]
Accrued payables	$ 13,132	$ 17,030
Accrued compensation and benefits	15,104	14,737
Accrued bonus	5,638	21,600
Accrued clinical expenses	14,998	11,707
Accrued taxes and other	1,343	1,356
Total accrued expenses and other current liabilities	$ 50,215	$ 66,430

Leases - Additional Information

Leases - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Lessee Lease Description [Line Items]
Operating lease option to extend	For the Company’s facility in Sunnyvale, California, there is an option to extend the lease for a period of seven years.
Operating lease cost	$ 3.4	$ 3.4
Variable lease cost	$ 1.3	$ 1.5
Minimum [Member]
Lessee Lease Description [Line Items]
Lessee, Operating Lease, Renewal Term	2 years 6 months
Maximum [Member]
Lessee Lease Description [Line Items]
Lessee, Operating Lease, Renewal Term	8 years 1 month 6 days

Leases - Schedule of Future Min

Leases - Schedule of Future Minimum Lease Payments Related to Company's Operating Lease Liability (Details) $ in Thousands	Jun. 30, 2023 USD ($)
Leases [Abstract]
2024 (remaining nine months)	$ 10,104
2025	15,474
2026	15,946
2027	15,472
2028	11,666
Thereafter	41,430
Total future operating lease payments	110,092
Less: imputed interest	(26,857)
Total operating lease liabilities	$ 83,235

Lease - The components of lease

Lease - The components of lease costs and other information related to leases (Details) - USD ($) $ in Millions	3 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Leases [Abstract]
Operating Lease, Cost	$ 3.4	$ 3.4
Variable lease cost	$ 1.3	$ 1.5

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) $ in Millions	Jun. 30, 2023 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Non-Cancelable Purchase Obligation	$ 29.5

Commitments and Contingencies_2

Commitments and Contingencies - Non-cancelable purchase obligations with a term of 12 months or longer (Details) $ in Millions	Jun. 30, 2023 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Total	$ 29.5

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) $ / shares in Units, $ in Millions		3 Months Ended	12 Months Ended
	Feb. 06, 2023 USD ($)	Jun. 30, 2023 Vote $ / shares shares	Mar. 31, 2023 $ / shares shares
Class Of Stock [Line Items]
Common stock, par value | $ / shares		$ 0.0001	$ 0.0001
Stock split description		Each share of Class B common stock is convertible into one share of Class A common stock any time at the option of the holder and is automatically converted into one share of Class A common stock upon transfer
Preferred stock, shares authorized		10,000,000	10,000,000
Preferred stock, par value | $ / shares		$ 0.0001	$ 0.0001
Preferred stock, shares issued		0	0
Preferred stock, shares outstanding		0	0
Proceeds from sales agent commission percentage	3%
VG Acquisition Sponsor LLC [Member]
Class Of Stock [Line Items]
Lockup Period		7 years	7 years
Earn Out Shares, Percentage		50%
Class A Common Stock [Member]
Class Of Stock [Line Items]
Common stock, shares authorized		1,140,000,000	1,140,000,000
Number of votes | Vote		1
Common stock, shares issued		304,011,272	293,020,474
Common stock, shares outstanding		304,011,272	293,020,474
Class A Common Stock [Member] | VG Acquisition Sponsor LLC [Member]
Class Of Stock [Line Items]
Earnout Shares		3,814,125	3,814,125
Trading days		20 days
Number Of Trading Days		20 days
Earn Out Shares, Percentage		50%
Number of trading days after commencing		30 days
Class B Common Stock [Member]
Class Of Stock [Line Items]
Common stock, shares authorized		350,000,000	350,000,000
Number of votes | Vote		10
Common stock, shares issued		168,084,278	168,179,488
Common stock, shares outstanding		168,084,278	168,179,488
Maximum [Member] | VG Acquisition Sponsor LLC [Member]
Class Of Stock [Line Items]
Share Price Thresholds Release From Lock Up | $ / shares		$ 15
Maximum [Member] | Cowen and Company LLC [Member] | Sales Agreement [Member]
Class Of Stock [Line Items]
Sale of Securities over a period of time | $	$ 500
Aggregate principal amount | $	$ 150
Minimum [Member] | Class A Common Stock [Member] | VG Acquisition Sponsor LLC [Member]
Class Of Stock [Line Items]
Share Price Thresholds Release From Lock Up | $ / shares		$ 12.50

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of common stock outstanding (Details) - shares	Jun. 30, 2023	Mar. 31, 2023
Class A Common Stock [Member]
Class of Stock [Line Items]
Common stock, shares authorized	1,140,000,000	1,140,000,000
Common Stock, Shares, Issued	304,011,272	293,020,474
Common stock, shares outstanding	304,011,272	293,020,474
Class B Common Stock [Member]
Class of Stock [Line Items]
Common stock, shares authorized	350,000,000	350,000,000
Common Stock, Shares, Issued	168,084,278	168,179,488
Common stock, shares outstanding	168,084,278	168,179,488

Stockholders' Equity - Schedu_2

Stockholders' Equity - Schedule of Common Stock Reserved for Issuance (Detail) - shares	3 Months Ended	12 Months Ended
	Jun. 30, 2023	Mar. 31, 2023
Class Of Stock [Line Items]
Outstanding stock options	68,386,690	68,050,752
Total shares of common stock reserved	156,005,891	166,884,802
2021 Equity Incentive Plan
Class Of Stock [Line Items]
Remaining shares available for future issuance under 2021 Incentive Equity Plan	28,640,341	55,922,182
Employee Stock Purchase Plan
Class Of Stock [Line Items]
Remaining shares available for future issuance under Employee Stock Purchase Plan	16,349,302	16,349,302
Restricted Stock Units [Member]
Class Of Stock [Line Items]
Outstanding restricted stock units	42,629,558	26,562,566

Equity Incentive Plans and St_3

Equity Incentive Plans and Stock-Based Compensation - Additional Information (Details) $ / shares in Units, $ in Thousands			1 Months Ended	3 Months Ended		12 Months Ended
		Jun. 10, 2021 shares	Nov. 30, 2021 USD ($) shares	Jun. 30, 2023 USD ($) $ / shares shares	Jun. 30, 2022 USD ($) $ / shares	Mar. 31, 2023 USD ($) shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares reserved for future issuance | shares				156,005,891		166,884,802
Granted | shares				2,018,253
Weighted-average grant date fair values of options granted | $ / shares				$ 1.43	$ 2.44
Intrinsic value of vested options exercised | $				$ 200	$ 1,500
Unrecognized stock-based compensation cost | $				$ 57,900
Weighted average period over which unrecognized compensation is expected to be recognized				2 years 4 months 24 days
Stock-based compensation expense | $				$ 51,100	30,462
Issuance of common stock related to early exercise of stock options, shares | shares				180,718
Total liabilities | $				$ 195,709		$ 228,659
Lemonaid Health, Inc. [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period			4 years
Unrecognized stock-based compensation cost | $				3,700
Weighted average period over which unrecognized compensation is expected to be recognized						2 years 3 months 18 days
Common stock granted subject to vest | shares			3,747,027
Common stock granted subject to vest, Weighted average grant date fair value | $			$ 43,900
General and Administrative [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense | $				22,000
General and Administrative [Member] | Lemonaid Health, Inc. [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense | $				24,700	2,700
General and Administrative [Member] | Secondary Sale Transaction [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense | $	[1]			34,576	12,170
Stock Option Activity [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Tax benefit recognized from stock option exercises | $				0	0
Restricted Stock Units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock-based compensation cost | $				$ 136,300
Weighted average period over which unrecognized compensation is expected to be recognized				2 years 10 months 24 days
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Option vest, term				4 years
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Option vest, term				3 years
2021 Incentive Equity Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares Available for Grant, Beginning balance | shares				22,839,019
Exercise price of stock options as a percentage of fair value of shares				110%
Share-based payment award, description				The number of shares of Class A common stock reserved for issuance under the 2021 Plan will automatically increase on January 1 of each calendar year, starting in 2022, in an amount equal to (i) 22,839,019 shares of Class A common stock, (ii) 3.0% of the aggregate number of shares of Class A common stock and Class B common stock outstanding, or (iii) a lesser number of shares determined by the Company’s Board of Directors prior to the applicable January 1.
Share-based payment award, expiration period				10 years
Share-based compensation terms of award				Options under the 2021 Plan have a contractual life of up to ten years. The exercise price of a stock option shall not be less than 100% of the estimated fair value of the shares on the date of grant, as determined by the Board of Directors.
2021 Incentive Equity Plan [Member] | Stock Option Activity [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of total stock holding				10%
2021 Incentive Equity Plan [Member] | Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock issued and outstanding, percentage				3%
2021 Incentive Equity Plan [Member] | Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price of stock options as a percentage of fair value of shares				100%
ESPP [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock issued and outstanding, percentage		(1.00%)
Potential annual increase in shares reserved for future issuance | shares		5,000,000
2006 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Granted | shares				0
2022 AIP [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense | $				$ 4,400	$ 5,000
Other current liabilities | $				$ 5,500		$ 18,900
Class A Common Stock [Member] | 2021 Incentive Equity Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares reserved for future issuance | shares		136,000,000
Exchange ratio of common stock				2.293698169
Class A Common Stock [Member] | 2021 Incentive Equity Plan [Member] | Lemonaid Health, Inc. [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares reserved for future issuance | shares			2,990,386	139,656,589
Class A Common Stock [Member] | 2021 Incentive Equity Plan [Member] | Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares reserved for future issuance | shares		136,000,000
Class A Common Stock [Member] | ESPP [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares reserved for future issuance | shares		11,420,000		16,349,302
Number of shares issued | shares				2,642,313
Class A Common Stock [Member] | 2022 AIP [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Issuance of common stock upon release of RSUs, shares | shares				8,961,053
[1] Includes $ 22.0 million of stock-based compensation expense related to the termination of a Former Lemonaid Officer d uring the three months ended June 30, 2023.

Equity Incentive Plans and St_4

Equity Incentive Plans and Stock-Based Compensation - Summary of the Activity Under the Stock Plan (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 30, 2023	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Balance as of March 31, 2023	68,050,752
Granted	2,018,253
Exercised	(180,718)
Cancelled/forfeited/expired	(1,501,597)
Balance as of June 30, 2023	68,386,690
Vested and exercisable as of March 31, 2023	49,302,828
Weighted-Average Exercise Price Beginning balance As Of March 31,2023	$ 4.20
Weighted-Average Exercise Price, Granted	2.06
Weighted-Average Exercise Price, Exercised	0.48
Weighted-Average Exercise Price, Cancelled/Forfeited/Expired	5.67
Weighted-Average Exercise Price, Ending balance As Of June 30, 2023	4.12	$ 4.20
Weighted-Average Exercise Price, Vested and exercisable March 31, 2023	$ 4.16
Weighted-Average Remaining Contractual Term (Years)	5 years 8 months 12 days	6 years
Weighted-Average Remaining Contractual Term (Years), Vested and Exercisable	4 years 9 months 18 days
Aggregate Intrinsic Value of Options Outstanding	$ 7,121	$ 10,621
Aggregate Intrinsic Value of Options Outstanding, Vested and Exercisable	$ 5,402

Equity Incentive Plans and St_5

Equity Incentive Plans and Stock-Based Compensation - Summary of the Value Stock Options (Details)	3 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term	5 years 9 months 18 days	6 years
Volatility	78%	76%
Risk-free rate	3.60%	2.80%
Dividend yield	0%	0%
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term	6 years	6 years 9 months 18 days
Volatility	79%	77%
Risk-free rate	3.90%	2.80%
Dividend yield	0%	0%

Equity Incentive Plans and St_6

Equity Incentive Plans and Stock-Based Compensation - Summary of the Restricted Stock Units (Details) - Restricted Stock Units [Member]	3 Months Ended
	Jun. 30, 2023 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unvested RSUs, beginning balance, Unvested as of March31, 2023 | shares	26,562,566
Unvested RSUs, Granted | shares	30,076,226
Unvested RSUs, Vested | shares	(10,757,178)
Unvested RSUs, Cancelled/forfeited | shares	(3,252,056)
Unvested RSUs ending balance unvested as of June 30, 2023 | shares	42,629,558
Weighted-Average Grant Date Fair Value Per Share, Beginning balance, Unvested as of March 31, 2023 | $ / shares	$ 4.73
Weighted-Average Grant Date Fair Value Per Share, Granted | $ / shares	2.15
Weighted-Average Grant Date Fair Value Per Share, Vested | $ / shares	2.64
Weighted-Average Grant Date Fair Value Per Share, Cancelled/forfeited | $ / shares	4
Weighted-Average Grant Date Fair Value Per Share, Ending balance, Unvested as of June 30, 2023 | $ / shares	$ 3.49

Equity Incentive Plans and St_7

Equity Incentive Plans and Stock-Based Compensation - Summary of the Stock-Based Compensation (Details) - USD ($) $ in Thousands		3 Months Ended
		Jun. 30, 2023	Jun. 30, 2022
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense		$ 51,100	$ 30,462
General and Administrative [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense		22,000
Secondary Sale Transaction [Member] | Cost of Revenue [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense		2,472	3,327
Secondary Sale Transaction [Member] | Research and Development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense		11,692	12,076
Secondary Sale Transaction [Member] | Sales and Marketing [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense		1,718	2,889
Secondary Sale Transaction [Member] | General and Administrative [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	[1]	34,576	12,170
Secondary Sale Transaction [Member] | Restructuring and Other Charges [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense		$ 642	$ 0
[1] Includes $ 22.0 million of stock-based compensation expense related to the termination of a Former Lemonaid Officer d uring the three months ended June 30, 2023.

Equity Incentive Plans and St_8

Equity Incentive Plans and Stock-Based Compensation - Summary of the Stock-Based Compensation (Parenthetical) (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 51,100	$ 30,462
Former Lemonaid Officer [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 22,000

Retirement Benefit Plans (Addit

Retirement Benefit Plans (Additional Information) (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Restructuring Cost and Reserve [Line Items]
Contributions cost	$ 900	$ 600
Annual compensation	$ 2,300
Annual compensation percentage	100%
Annual compensation of employee contributions	100%
Annual compensation and contribution limits	The Company matches the greater of 100% of the first 2% or 100% of the first $2,300 (subject to annual compensation and contribution limits) of employee contributions.
Restructuring charges	$ 4,217	$ 0
Restructuring Charge
Restructuring Cost and Reserve [Line Items]
Restructuring charges	4,200
Other restructuring charges	3,600
Severance payments	$ 600

Restructuring -Schedule of rest

Restructuring -Schedule of restructuring and related costs (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Restructuring Cost and Reserve [Line Items]
Accrued restructuring costs included in accrued expenses and other current liabilities as of March 31, 2023	$ 0
Restructuring charges incurred during the period	4,217	$ 0
Amounts paid during the period	(3,290)
Accrued restructuring costs included in accrued expenses and other current liabilities as of June 30, 2023	$ 927

Income Taxes - Schedule of loss

Income Taxes - Schedule of loss before provision for (benefit from) income taxes (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Loss before income taxes	$ (104,624)	$ (89,786)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Operating Loss Carryforwards [Line Items]
Income tax benefit	$ 0	$ 254

Net Loss Per Share Attributab_3

Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail) - $ / shares	3 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Earnings Per Share [Abstract]
Dividends paid in shares	$ 0	$ 0

Net Loss Per Share Attributab_4

Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic And Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Numerator:
Net loss	$ (104,624)	$ (89,532)
Denominator:
Weighted-average shares used to compute net loss per share, basic	462,254,442	446,505,329
Weighted-average shares used to compute net loss per share, diluted	462,254,442	446,505,329
Net loss per share of Class A and Class B common stock attributable to common stockholders:
Net loss per share attributable to common stockholders, basic	$ (0.23)	$ (0.20)
Net loss per share attributable to common stockholders, diluted	$ (0.23)	$ (0.20)
Class A Common Stock [Member]
Numerator:
Net loss	$ (66,563)	$ (48,584)
Denominator:
Weighted-average shares used to compute net loss per share, basic	294,089,562	242,292,436
Weighted-average shares used to compute net loss per share, diluted	294,089,562	242,292,436
Net loss per share of Class A and Class B common stock attributable to common stockholders:
Net loss per share attributable to common stockholders, basic	$ (0.23)	$ (0.20)
Net loss per share attributable to common stockholders, diluted	$ (0.23)	$ (0.20)
Class B Common Stock [Member]
Numerator:
Net loss	$ (38,061)	$ (40,948)
Denominator:
Weighted-average shares used to compute net loss per share, basic	168,164,880	204,212,893
Weighted-average shares used to compute net loss per share, diluted	168,164,880	204,212,893
Net loss per share of Class A and Class B common stock attributable to common stockholders:
Net loss per share attributable to common stockholders, basic	$ (0.23)	$ (0.20)
Net loss per share attributable to common stockholders, diluted	$ (0.23)	$ (0.20)

Net Loss per Share Attributab_5

Net Loss per Share Attributable to Common Stockholders - Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details) - Class A Common Stock [Member] - shares	3 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Earnings Per Share Basic [Line Items]
Outstanding stock options	114,127,969	101,792,006
ESPP [Member]
Earnings Per Share Basic [Line Items]
Outstanding stock options	2,776,927	3,456,238
Stock Option Activity [Member]
Earnings Per Share Basic [Line Items]
Outstanding stock options	68,386,690	71,980,548
Restricted Stock Units [Member]
Earnings Per Share Basic [Line Items]
Outstanding stock options	42,629,558	23,076,570
Shares Subject to Vesting [Member]
Earnings Per Share Basic [Line Items]
Outstanding stock options	334,794	3,278,650

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Subsequent Event [Line Items]
Stock-based compensation expense		$ 51,100	$ 30,462
Subsequent Event [Member]
Subsequent Event [Line Items]
Severance and benefit continuation charges	$ 3,000
Stock-based compensation expense	$ 800